[go: up one dir, main page]

CN1248737C - 含有皂苷和固醇的疫苗 - Google Patents

含有皂苷和固醇的疫苗 Download PDF

Info

Publication number
CN1248737C
CN1248737C CNB021529795A CN02152979A CN1248737C CN 1248737 C CN1248737 C CN 1248737C CN B021529795 A CNB021529795 A CN B021529795A CN 02152979 A CN02152979 A CN 02152979A CN 1248737 C CN1248737 C CN 1248737C
Authority
CN
China
Prior art keywords
antigen
vaccine combination
mpl
virus
cholesterol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB021529795A
Other languages
English (en)
Other versions
CN1480214A (zh
Inventor
纳撒利·M·－J·C·加肯
马丁·弗里德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
SmithKline Beecham Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26306923&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1248737(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9508326.7A external-priority patent/GB9508326D0/en
Priority claimed from GBGB9513107.4A external-priority patent/GB9513107D0/en
Application filed by SmithKline Beecham Biologicals SA filed Critical SmithKline Beecham Biologicals SA
Publication of CN1480214A publication Critical patent/CN1480214A/zh
Application granted granted Critical
Publication of CN1248737C publication Critical patent/CN1248737C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

本发明涉及一种含有抗原，免疫活性的皂苷组分以及固醇的疫苗组合物。

Description

含有皂苷和固醇的疫苗
本申请是于1997年10月23日向中国专利局提交的中国中请号为96193443.3的国际申请(国际申请号为PCT/EP96/01464，国际公开号为WO96/33739)的分案申请。
技术领域
本发明涉及新的疫苗配方及其制备方法和在医学中的应用。本发明特别涉及那些含有一种抗原，一种来源于Quillaja Saponaria Molina树皮的免疫活性组分如QS21，以及一种固醇的疫苗。
背景技术
来源于南美洲的Quillaja Saponaria Molina树皮的免疫活性的皂苷组分具有佐剂的活性是本领域内众所周知的。比如QS21(也称为QA21)，一种HPLC纯化的来源于Quillaja Saponaria Molina树的组分及其制备方法公开于(作为QA21)美国专利5,057,540中。皂树皮皂苷作为佐剂也已由Scott等人披露(Int.Archs.Allergy Appl.Immun.，1985，77，409)。然而，QS21用作佐剂却伴随着某些缺憾。例如，将QS21作为游离分子注射入哺乳动物时，可以发现坏死，也就是说在注射部位发生了局部组织坏死。
现已意外地发现，在注射部位的坏死可以通过使用含有QS21和固醇相组合的制剂而得以避免。优选的固醇包括β-谷固醇，豆固醇，麦角固醇，麦角钙化(固)醇和胆固醇。这些固醇是本领域内众所周知的，比如胆固醇作为一种天然的发现于动物脂肪的固醇见于默克索引(Merck Index)，第11版，341页。
发明内容
因此，本发明的第一个方面是提供一种含有抗原，免疫活性的皂苷组分和固醇的疫苗组合物。本发明的组合物优选地含有大体上纯的免疫活性皂苷组分。本发明的组合物优选地含有大体上纯的QS21，也就是说该QS21是至少90％纯的，优选地是95％纯的而最优选地是98％纯的。其它在本发明的组合物中有用的免疫活性皂苷组分包括QA17/QS17。含有QS21和胆固醇的本发明组合物相比于无胆固醇的组合物表现出了降低的反应原性，而其佐剂的效果却不变。此外，已知该QS21在pH约为7或更高的碱性环境中降解。本发明还有一个优越性是QS21在含有胆固醇的配方中对碱介导的水解的稳定性增强。
本发明优选的组合物是形成了脂质体结构的那些。那些其中的固醇/免疫活性皂苷组分形成了ISCOM结构的组合物也构成了本发明的一个方面。
QS21∶固醇的比率通常为1∶100到1∶1的重量比(W/W)。优选固醇过量存在，而QS21∶固醇的比率至少为1∶2W/W。用于对人类给药的疫苗中，QS21和固醇通常是以每剂量大约1微克到100微克的范围，优选地为大约10微克到50微克的范围存在。
该脂质体优选地含有中性脂，如磷脂酰胆碱，其优选地在室温下是非晶态的，如蛋黄磷脂酰胆碱，二油酰磷脂酰胆碱或二月桂酰磷脂酰胆碱。该脂质体也可以含有带电的脂质，其能提高脂质体-QS21结构(其中的脂质体是由饱和脂所构成的)的稳定性。在这些情况下，该带电的脂质的量优选地为1-20％W/W，最优选地为5-10％。固醇对磷脂的比率为1-50％(mol/mol)，最优选地为20-25％。
本发明的组合物优选地含有MPL(3脱-氧-酰单磷酰类脂A，也称作3D-MPL)。而作为3种脱-氧-酰化的单磷酰类脂A和4，5或6酰化的链的混合物的3D-MPL见于GB 2220211(Ribi)中并由蒙大拿的Ribi免疫化学公司制备。国际专利申请92/116556公开了一个优选的存在形式。
本发明的合适的组合物是那些其中的脂质体最初是在无MPL下制备，然后，再加入，优选地为100nm的颗粒的MPL。因此，该MPL没有包含在囊泡膜内(称为MPL外)。而那些其中的MPL包含在囊泡膜内的组合物(称为MPL内)也构成了本发明的一个方面。该抗原可以包含于囊泡膜内或外。优选地，可溶性抗原是包含于膜外的而疏水性的或者脂化的抗原则既可以包括于膜外又可以包括于膜内。
本发明的疫苗通常无需任何特殊的载体而可以在水或者其它的药物可接受的缓冲液中配制。在某些情况下可能有益的是本发明的疫苗还可以含有明矾或者存在于水包油的乳剂中，或者其它合适的赋形剂内，如脂质体，微球体或者微囊化的抗原颗粒。
该疫苗配方优选地含有一种能够诱发可以抵抗人类或者动物病原体的免疫反应的抗原或者抗原组合物。在本领域已知的抗原或者抗原组合物可以用于本发明的组合物中，其包括多糖类抗原，源于HIV-1的(如gP120或gP160)，任何猫科动物免疫缺陷病毒，人或动物疮疹病毒，如gD或其衍生物或源于HSVI1或HSV2的直接早期蛋白如ICP27，巨细胞病毒(特别是人)(如gB或其衍生物)，水痘带状疱疹病毒(如gPI，II或III)的抗原或者抗原组合物，或者源于诸如乙肝病毒的肝炎病毒的抗原如乙肝表面抗原或其衍生的甲肝病毒，丙肝病毒和戊肝病毒的抗原或者抗原组合物，或者来源于其它病毒性致病原的抗原，如呼吸道合胞病素(如美国专利5,149,650中公开的HSRV F和G蛋白或其免疫片段或者美国专利5,194,595中公开的含有来源于HSRV蛋白F和G的免疫片段的嵌合多肽，如FG糖蛋白)，来源于脑膜炎菌株如甲，乙和丙型脑膜炎，肺炎链球菌，人乳头瘤病毒，流感病毒，B型流感嗜血杆菌(Hib)，EB病毒(EBV)的抗原，或者来源于细菌性病原如沙门氏菌，疏螺旋体属(例如OspA或OspB或其衍生物)，或者衣原体属，或者博代杆菌属如P.69，PT和FHA的抗原，或者来源于寄生虫如疟原虫属或弓形虫属的抗原。
HSV糖白D(gD)或衍生物是优选的疫苗抗原。其位于病毒膜上，并且也见于感染的细胞的胞质中(Eisenberg R.J.等人；病毒学杂志1980 35 428-435)。其含有包括一个信号肽的393个氨基酸且分子量约为60KD。它可能是所有HSV被膜糖蛋白中特性最优者(Cohen等人，病毒学杂志60 157-166)。已知其在体内对病毒吸附于细胞膜起着重要的作用。此外，糖蛋白D在体内已表现出能诱发中和抗体并防止动物受致命的攻击。平头型的gD分子没有C末端锚形区且能够以可溶蛋白形式在哺乳动物细胞内产生，然后再分泌到该细胞培养的上清液中。该可溶型的gD是优选的。平头型的gD分子的生产见于EP 0139417中。该gD优选地来源于HSV-2。本发明的一个实施例是308个氨基酸平头型HSV-2糖蛋白D，其含有天然糖蛋白中的氨基酸1-306，并在无膜锚形区的平头型蛋白的C末端加入天冬酰胺和谷氨酰胺。此类蛋白包括信号肽，而信号肽裂解后便于该成熟的含有283氨基酸的可溶蛋白从宿主细胞中分泌出来。
在本发明的另一方面，乙肝表面抗原是优选的疫苗抗原。
这里用的“乙肝表面抗原”或者‘HBsAg’一词包括任何HBsAg抗原或其表现出HBV表面抗原的抗原性的片段。可以理解的是，除了该HBsAg抗原的226个氨基酸(见于Tiollais等人，自然，317,489(1985)及其中的参考文献)外，若需要，这里所述的HBsAg可以包括全部的或者部分的上述参考文献及EP-A-0278940中所述的一种前-S序列。特别地，该HBsAg可以包括含有一种氨基酸序列的多肽，该氨基酸序列先后分别包括对应于一种近血清型的乙肝病毒的开放阅读框的HBsAg的L-蛋白的12-52残基、133-145残基、175-400残基(此多肽是指L*；见于EP 0414374)。在本发明的范围内的HBsAg还可以含有EP 0198474(Endotronics)中所述的前-S1-前S2-S多肽或者其严格的如EP 0304578(Mc Cormick和Jones)中所述的类似物。这里所述的HBsAg还能指突变体，比如WO 91/14703或欧洲专利申请0511855A1中所述‘逃避突变体’，尤其指在其中的145位氨基酸处由精氨酸取代了甘氨酸的HBsAg。
该HBsAg一般是微粒型的。该微粒可以单独含有诸如S蛋白或者是组合微粒，如(L*，S)，其中的L*如上文定义而S则指HBsAg的S-蛋白。该微粒最好是以在酵母中表达的形式。
乙肝表面抗原S-蛋白的制备是有充分的文献报道的。例如见于Harford等人(1983)，发育生物学规范(Develop.Biol.Standard)54，125页，Gregz等人(1987)，生物技术，5,479页，EP 0226846，EP 0299108及其中的参考文献。
在本发明的范围内的配方还可以含有抗-肿瘤抗原并用于肿瘤的免疫治疗。
通常，疫苗的制备见于Voller等人编辑的疫苗新趋势和进展(Park大学出版社，巴尔的摩，马里兰州，美国，1978)。在脂质体中成囊见于诸如Fullerton，美国专利4,235,877中。和蛋白质结合成大分子则公开于诸如Lkhite，美国专利4,372,945和Armor等人的美国专利4,474,757。
将每个疫苗剂量中的蛋白量定为能在常规疫苗中诱发免疫保护反应却不引起明显的副作用的量。此量的变化依赖于使用的具体免疫原以及其存在形式。一般地，所期望的是每个剂量中包含有1-1000微克蛋白，优选地为2-100微克，最优选地为4-40微克。微粒疫苗的最佳量可以通过包括检测实验对象的合适的免疫反应在内的常规研究而确定。初次接种后，受试对象还可以在充分的时间间隔后再接受一次或者几次加强接种。
本发明的配方既可用于预防，又可用于治疗目的。
相应地，本发明还有一个方面就是提供了本发明的疫苗的治疗病人的应用。本发明提供了一个包括对病人给于有效剂量的本发明的疫苗的治疗方法。本发明尤其是提供了一个包括对病人给于有效剂量的本发明的疫苗从而治疗病毒性的，细菌性的，寄生虫性的感染或者肿瘤的方法。
下列实施例和数据阐明了本发明。
附图说明
图1：用含有或者不含有胆固醇的脂质体抑制QS21的比较
图2：将20μg QS21在含胆固醇的SUV存在且pH9，37℃下培育16小时
图3(a)：balb/c小鼠用有QS21存在的gD120足垫注射进行免疫后，测定了脾细胞中胞毒T淋巴细胞的活性。
图3(b)：balb/c小鼠用有QS21+含有胆固醇的SUV存在的gD120足垫注射进行免疫后，测定了脾细胞中胞毒T淋巴细胞的活性。
具体实施方式
1.1制备脂质体的方法
将置于有机溶剂中的脂质(如来源于蛋黄的或者合成的磷脂酰胆碱)和胆固醇的混合物在真空(或者惰性气流)下干燥。然后，加入一种水溶液(如磷酸盐缓冲液)，振荡该容器直止脂质全部进入悬浊液中。然后，将该悬浊液微流化直至该脂质体大小降至100nm，再通过0.2μm的滤器进行无菌过滤。挤压和声处理可以代替该步骤。通常，胆固醇∶磷脂酰胆碱的比率是1∶4(W/W)，加入水溶液使胆固醇的终浓度为5-50mg/ml。如果将包含MPL的有机溶液加入溶于有机溶液的脂质内，那么最终的脂质体在膜内含有MPL(称为MPL内)。
将该脂质体的大小规定为100nm并且是指SUV(小单室囊泡)。如果反复冻融该溶液，那么囊泡融合成大小为500nm至15μm的大的多室结构。该脂质体本身是可以长期稳定的且没有致融能力。
1.2配制步骤
将QS21水溶液加入该脂质体中。然后，将该混合物加入到抗原溶液中，并且若需要，还可以含有呈100nm微粒状的MPL。
1.3含有胆固醇的脂质体抑制QS21的溶解活性
当QS21加入到红细胞中时可以溶解红细胞使其释放血红蛋白。该溶解活性也可以使用含有存在于膜内的胆固醇以及捕获的荧光染料，羧荧光素的脂质体进行检测-当该脂质体被溶解时便释放染料，而该染料又可用荧光分光镜进行检测。若在荧光脂质体的膜内不含胆固醇，那么不会观察到溶解作用。
若在加入到红细胞中之前，将该QS21和含有胆固醇的脂质体共同培育，那么该红细胞的溶解依赖于胆固醇对QS21的比率而降低。若使用的比率为1∶1，则没有检测到溶解活性。如果该脂质体不含胆固醇，则抑制溶解需要比QS21过量1000倍的磷脂。
用荧光脂质体检测溶解活性有同样的结果。在图1中，通过荧光检测了用无胆固醇(每mg/ml蛋黄磷脂酰胆碱)或含有胆固醇(每mg/ml磷脂酰胆碱，500μg胆固醇)的脂质体处理的4μgQS21的溶解活性。
数据显示QS21在膜内以特定的方式和胆固醇结合，从而引起溶解(细胞的或者荧光脂质体的)。如果QS21首先和脂质体中的胆固醇结合，那么不再溶解细胞或其它脂质体。这要求胆固醇∶QS21(W/W)的最低比率为0.5∶1。
胆固醇在水溶液中不溶且也不能形成稳定的悬浊液。当有磷脂存在时，该胆固醇存在于磷脂双分子层中并能形成称为脂质体的稳定的囊泡悬浊液。为了避免需要加入磷脂而试验了一个可溶的衍生物。聚氧乙烷胆固醇癸二酸盐在水中的溶解能力达到60mg/ml，然而，既使使用超过QS212000倍的量，也没有检测到QS21溶解活性的降低。
1.4含有胆固醇的脂质体增加了QS21的稳定性
QS21在pH约为7的环境中极易水解。该水解作用可以在反相HPLC上通过检测对应于QS21的峰的降低而测定。例如，图2表明在pH9的37℃下，16小时内有90％的QS21被水解。如果在该QS21中以2∶1的比率(胆固醇：QS21 W/W)加入含有胆固醇的脂质体，则在同样的条件下没有检测到水解作用。若比率为1∶1，则有10％的QS21被降解。
可以得出结论的是，当QS21和含有胆固醇的脂质体结合时，其变得极不易受碱介导的水解作用。据报道，该水解产物经注射给药，无佐剂活性，因而，含有QS21的疫苗必需在酸性pH中配制并保藏在4℃以维持佐剂组合物。使用脂质体可以避免该项要求。
1.5反应原性研究：
在小鼠胫骨肌注射5μgQS21(或者洋地黄皂苷)和逐步增加量的脂质体(以胆固醇的μg表示)。溶解活性表示为相当于QS21量(μg)，其含义是要达到样品中同样的溶血作用所需的QS21的量。
处死动物后，目测评分注射位点的肌肉的充血，坏死和毒性状况。
  配方   水解活性μg   充血   坏死   毒性
  QS21+PBS   5   +++   ±   +++
  QS21+1μg胆固醇(SUV)   4   +++   +   ++++
  QS21+5μg胆固醇(SUV)   0   -   -   ±
  QS21+25μg胆固醇(SUV   0   ±   -   +
  单独SUV   0   -   -   -
  洋地黄皂苷   5   -   -   ±
  PBS   0   -   -   -
数据显示当溶解活性由于含有胆固醇的脂质体的加入而消除后，源于QS21的毒性也随之消除。
1.6免肌内反应原性
U.I./L值
  实验   配方   第0天 溶血作用   第1天 溶血作用   第3天 溶血作用
  兔n°1免n°2兔n°3兔n°4兔n°5 QS21 50μg   107811166605923400   ±   86504648481956627528   152314356846841736
  均值SD   13691160   62611757   1212495
  实验   配方   第0天 溶血作用   第1天 溶血作用   第3天 溶血作用
  兔n°6兔n°7兔n°8兔n°9兔n°10 QS2150μgSUV内的胆固醇50μg(1∶1)   5965406115211092 ±   16706021873507787   460594803616555
  均值SD   672238   1088636   606125
  实验   配方   第0天 溶血作用   第1天 溶血作用   第3天 溶血作用
  兔n°11兔n°12兔n°13兔n°14兔n°15 QS21 50μgSUV内的胆固醇150μg(1∶3)   3328314645281027   344662356720568   387694519614849
  均值SD   637285   530173   613175
  实验   配方   第0天 溶血作用   第1天 溶血作用   第3天 溶血作用
  兔n°16兔n°17兔n°18兔n°19兔n°20 QS21 50μgSUV内的胆固醇250μg(1∶5)   5404984428223182 ±   7694047178012410   745471(4535)925960
  均值SD   10971175   1020793   775224   (1527)(1692)
  实验   配方   第0天 溶血作用   第1天 溶血作用   第3天 溶血作用
  兔n°21兔n°22兔n°23免n°24兔n°25 PBS   3216606501395429 ±   290535603(3545)323   378755473(5749)263
  均值SD   691419   438155   (1059)(1396)   467210   (1523)(2369)
数据显示在配方中加入含有胆固醇的脂质体可以显著地降低QS21所致的CPK(肌酸磷酸激酶)升高。由于CPK的升高是肌肉损伤的量度，所以其意味着肌肉损伤的降低且已经组织病毒学证实。
1.7脂质体-QS21的复合物和明矾相结合。
将QS21和含有过量的胆固醇以及放射性胆固醇的中性脂质体一起培育，然后，再和溶于PBS中的明矾(Al(OH)3)一起培育。单独的中性脂质体和QS21都不能和溶于PBS的明矾相结合，而带有负电荷的脂质体也不能。然而，当QS21和中性脂质体一起都可以和明矾相结合。该上清液既不含QS21(苔黑酚试验检测)也不含放射性胆固醇。
这表明QS21已结合于脂质体且允许该脂质体-QS21结合物结合于明矾。这可能产生于由QS21加于该脂质体的负电荷，或者脂质体上的疏水区的暴露。该结果也意味着QS21不能从膜中抽提胆固醇。
这表明本发明的组合物可用于基于明矾的疫苗中。
1.8脂质体样QS21/MPL和游离QS21+MPL的抗体的比较及CMI诱发
用挤压技术制备SUV(EYPC∶胆固醇∶MPL 20∶5∶1)。
对MPL外而言，脂质体在无MPL的条件下制备并再以100nm的微粒态加入MPL。
QS21先于抗原加入。胆固醇∶QS21＝5∶1(W/W)
在抗原加入前，通过3次冻融SUV制备MLV。
对捕获抗原而言，抗原在冻融前加入到SUV中并在冻融后加入QS21。抗原成囊＝5％内，95％外。在小鼠(gD用balb/c，RTSs用BIOBR)的足垫处注射两次。gD是来源于单疱疹病毒的糖蛋白。RTSs是指经过遗传改良而含有一个来源于原生团恶性子孢子(Plasmodiium falciparum sporozoit)的抗原表位的乙肝表面抗原(HBsAg)。
  ag＝10μgRTSs          强化后15天的抗HBsAg滴度
  配方   IgG1   IgG2a   IgG2b
  SUV/QS+MPL(外)              +Ag   1175   10114   71753
  MLV/QS+MPL(外)              +Ag   2247   11170   41755
  MLV/QS/MPL(内)              +Ag   969   7073   18827
  MLV/QS/MPL(内)/Ag(内)       +Ag   1812   2853   9393
  QS+MPL                      +Ag   372   9294   44457
                               Ag   ＜100   ＜100   ＜100
  SUV/QS+MPL(外)   ＜100   ＜100   ＜100
  MLV/QS/MPL(内)   ＜100   ＜100   ＜100
  ag＝20μg gD   抗gD          CMI
  配方   IgG IFN-γ96小时(pg/ml)  IL248小时pg/ml
  SUV/QS+MPL(外)         +Ag  2347   1572   960
  SUV/QS/MPL(内)         +Ag  2036   1113   15
  MLV/QS+MPL(外)         +Ag  1578   863   15
  MLV/QS/MPL(内)         +Ag  676   373   15
  MLV/QS/MPI(内)/Ag(内)  +Ag  1064   715   15
  QS+MPL                 +Ag  1177   764   15
                          Ag  ＜100   567   44
  SUV/QS+MPL(外)  ＜100   181   15
  MLV/QS/MPL(内)  ＜100   814   105
数据显示：SUV/QS+MPL(外)诱导出至少和QS21+MPL相当的高抗体滴度，以及诱导出作为细胞介导免疫标记的IL-2，而抑制QS21的反应原性。
另外，用HSV gD作抗原在balb/c小鼠中对比QS21和有胆固醇(SUV)存在的QS21第二个实验的结果如下：
                   II后第7天同模标本
  配方SUV/QS21+MPL外SUV/QS21/MPL内QS21+MPLSUV/QS21+MPL外QS21SUV/QS21   抗原gD(5μg)gD(5μg)gD(5μg)无gD(5μg)gD(5μg)   II后第7天IgG(GMT)   II后第14天IgG(GMT)   IgG1μg/ml ％   IgG2aμg/ml ％   IgG2bμg/ml  ％
  2029012566105040346811253   1634310731101680413211589   3314182000156484   26443406657   716412285067304   56444802836   222     17111     12107     180       014      665      8
1.9比较分别加上脂质体样的MPL/QS21和游离的MPL/QS21的gD120
脂质体＝在膜内含MPL的SUV
胆固醇∶QS21＝6∶1
在一次免疫接种后两周检测反应
  配方   增殖   IFN-gng/ml   IL2pg/ml   IL5pg/ml
  SUV/MPL/QS21+Ag   12606   16.6   59   476
  MPL+QS21+Ag   16726   15.8   60   404
第二次免疫接种后：
  配方   增殖   IFN-gng/ml   IL4pg/ml   IL5pg/ml
  SUV/MPL/QS21+Ag   12606   135   0   250
  MPL+QS21+Ag   16726   60   0   500
数据显示QS21和含有胆固醇的脂质体以及MPL相结合能诱发出相当于MPL+QS21的Th1/Th0反应。
在此胆固醇对QS21的比率下，QS21对兔子无毒性(用CPK作指标)
在第二个试验中，balb/c小鼠用有QS21或者QS21+含有胆固醇的SUV存在的gD120足垫注射进行免疫。测定了脾细胞中胞毒T淋巴细胞的活性，如图3(a)和图3(b)所示。
这表明单独的QS21诱发CTL活性，而在有含胆固醇的脂质体存在的情况下的QS21至少能诱发出和单独的QS21相当或者更好的CTL活性。
2.疫苗
2.1HBsAgL*，S颗粒的配制
HBsAgL*，S颗粒可如下配制：
将10μg HBsAg L*，S颗粒/剂在室温下搅拌培育一小时。用注射用水和PBS溶液调节该体积并最终用QS21(10μg/剂)的水溶液将体积定为70μl/剂。pH维持在7±0.5。
使用1和50μg HBsAg L*，S可制备类似的配方，并且还可以使用HBsAg S抗原。
这些配方可在旱獭替代治疗模型中用旱獭HBV抗原作模型进行检测。
旱獭模型
DQ QS21(即QS21/胆固醇或抑制的QS21)可在长期注射病毒的旱獭的治疗模型中进行检测。具体的旱獭乙肝病毒疫苗可以和如此的QS21或者DQ混和并且可以带有或者不带MPL，其每月均对动物给药，连续六个月。该疫苗的效应可通过病毒DNA的清除率来评估。
2.2豚鼠模型(HSV)
2.2.1预防模型
将12只为一组的雌Harttey豚鼠用下述配方在零天和第28天肌内注射：
第一次实验：
gD 5μg+QS21 50μg+含50μg胆固醇的SUV
gD 5μg+QS21 100μg+含100μg胆固醇的SUV
gD 5μg+QS21 50μg+含250μg胆固醇的SUV
gD 5μg+QS21 50μg
第二次实验：
gD 5μg+MPL12.5μg+QS21 12.5μg+含62.5μg胆固醇的SUV，或者不处理。
在第二次免疫接种的第14和28天对动物进行放血，测定血清中gD-特异的ELISA抗体滴度。
然后，用105空斑单位(pfu)的HSV-2MS株阴道注射攻击动物。在第4-12天每天对动物进行初期疱疹损伤评估。得分如下：
阴道损伤：
-流血＝0.5
-充血1或2天但没有流血＝0.5
-充血并流血1天＝1
-充血但没有流血且持续至少3天＝1
外部疱疹水疱：
-＜4个小水疱＝2
-＞＝4个小水疱或者一个大水疱4＞＝4个大瘤8融合瘤＝16
-在全部外生殖区的融合大瘤＝32
结果如下表所示：
预防模型
实验1(chol是指含有胆固醇的SUV)
  数量            配方                                          初期病变
1211121212 gD/QS21 50μggD/QS21 50μg-chol 1/5gD/QS21 50μg-chol 1/1gD/QS21 50μg-chol 1/1未处理   无损伤的动物百分数(％)   阴道损伤发病率(％)   外部损伤发病率(％)   初期感染系数** 相对于对照组的降低   损伤严重性*中数 数目
  50641005025   33180330   171801775   7367054996   93％93％100％95％-   1.502.50-0.7555.00   64-69
实验2
数量 配方           Ab滴度(GMT)                                          初期病变
1212 gD/QS21/SUV/MPL未处理        ELISA   中和第二次后28天   无损伤动物％   阴道损伤发病率％   外部损伤发病率％   初次感染系数**   相对于对照组的降低   损伤严重性*中数n 数量
第二次后14天 第二次后28天
47006＜400 31574＜400   449＜50   58.3316.67   33.338.33   8.3375.00   37.50587.50   94％-   1.0011.50   510
*感染后4-12天内损伤评分的和(无损伤的动物不考虑)
损伤评分：无损伤(0)，阴道损伤(0.5或1)，外部皮肤水疱(2，4，8或16)
**初期感染系数＝和数(最大得分i)×(发病率％)；而j＝0，0.5，1，2，4，8或16
该图表显示出在预防模型中，用gD/MPL/QS21/SUV免疫接种诱发了极高水平的对初期病变的预防保护效应。无论是外部损伤发病率还是损伤的严重性在用gD/MPL/QS21/SUV免疫接种的动物组中均有极大程度的降低。
2.2.2治疗模型
在该治疗模型中，首先用105pfu HSV-2MS株攻击雌性的Hartloy豚鼠。将带有疱疹损伤的动物再进行随机分组，每组16只。
在第21天和42天，用下列配方之一免疫动物：-gD+MPL50μg+QS21 50μg+含250μg胆固醇的SUV-gD+Al(OH)3+MPL50μg+QS21 50μg+含有250μg胆固醇的SUV或者不处理。
从第22-75天每天监测动物以评估疾病的复发状况。评分如预防模型中所述。结果如下列图表所示：
治疗模型
  数量 配方            严重性*          持续时间**          发作病例数***
    中数   相对于对照组所降低的百分数(％)   中数   相以于对照组所降低的百分数(％)     中数   相对于对照组所降低的百分数(％)
  161516 gD+MPL+QS21+SUVgD+Al(OH)3+MPL+QS21+SUV未处理     9.008.5015.75   43％46％-   7.007.008.50   18％18％-     3.003.003.50   14％14％-
*感染后第22-75天的损伤得分的和
**感染后第22-75天，实验动物复发损伤的总天数
***感染后第22-75天的复发发作数例数。发作在先且在随后的一天无损伤，其特征是至少有两天的红斑(得分＝0.5)或者一天的外部水疱(得分＞＝2)
免疫治疗在第21天和第42天进行。
该结果表明在HSV-2感染的治疗模型中也能诱导出良好的保护水平。用含或不含明矾的gD/MPL/QS21/SUV免疫对复发疾病的严重性的中位数产生了显著的影响。它也略微降低了发作病例数和持续时间(见表)。

Claims (14)

1.一种含有抗原、QS21和固醇的疫苗组合物，其中的佐剂系统还包含一种载体或3脱-氧-酰单磷酰类脂A，即3D-MPL，所述QS21为至少90％纯且QS21与固醇的比例为1∶1-1∶100w/w。
2.根据权利要求1所述的疫苗组合物，其中抗原来源于人类免疫缺陷病毒、猫科动物免疫缺陷病毒、水痘带状疱疹病毒、单纯疱疹病毒I型、单纯疱疹病毒II型、人巨细胞病毒、甲、乙、丙或戊型肝炎病毒、呼吸道合胞病毒、人乳头瘤病毒、流感病毒、Hib、脑膜炎病毒、沙门氏菌属、奈瑟菌属、疏螺旋体属、衣原体属、博代杆菌属、疟原虫属或者弓形虫属。
3.根据权利要求1所述的疫苗组合物，其含有来源于肿瘤的抗原。
4.根据权利要求1所述的疫苗组合物，其中抗原来源于疟原虫抗原、HIV抗原、HBV抗原或HSV抗原。
5.根据权利要求1所述的疫苗组合物，其是在脂质体结构中。
6.权利要求5的疫苗组合物，其中的QS21至少为95％纯。
7.权利要求5的疫苗组合物，其中的QS21至少为98％纯。
8.权利要求5的疫苗组合物，其在脂质体的膜内包含3D-MPL。
9.用于医药的根据权利要求1-8任一项所述的疫苗组合物。
10.权利要求1-8任一项所述的疫苗组合物在制备用于预防性治疗病毒感染，细菌感染或者寄生虫感染的疫苗中的应用。
11.权利要求1-8任一项所述疫苗组合物在制备用于免疫治疗癌症的疫苗中的应用。
12.制备权利要求5所述疫苗组合物的方法，其包括以下步骤：
a)制备含固醇的脂质悬浮剂；
b)使所述脂质悬浮剂微流化，直至脂质体大小缩至100nm；
c)添加载体，或添加含有3D-MPL的有机溶液；
d)添加QS21；
e)与抗原混合。
13.制备权利要求1-8任一项所述疫苗组合物的方法，其包括将QS21及固醇与抗原或抗原组合物混合。
14.权利要求13的方法，其中固醇是胆固醇。
CNB021529795A 1995-04-25 1996-04-01 含有皂苷和固醇的疫苗 Expired - Lifetime CN1248737C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9508326.7A GB9508326D0 (en) 1995-04-25 1995-04-25 Vaccines
GB9508326.7 1995-04-25
GBGB9513107.4A GB9513107D0 (en) 1995-06-28 1995-06-28 Vaccines
GB9513107.4 1995-06-28

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN96193443A Division CN1111071C (zh) 1995-04-25 1996-04-01 含有皂苷和固醇的疫苗

Publications (2)

Publication Number Publication Date
CN1480214A CN1480214A (zh) 2004-03-10
CN1248737C true CN1248737C (zh) 2006-04-05

Family

ID=26306923

Family Applications (3)

Application Number Title Priority Date Filing Date
CN96193443A Expired - Lifetime CN1111071C (zh) 1995-04-25 1996-04-01 含有皂苷和固醇的疫苗
CNB021529795A Expired - Lifetime CN1248737C (zh) 1995-04-25 1996-04-01 含有皂苷和固醇的疫苗
CNB021529787A Expired - Lifetime CN1289065C (zh) 1995-04-25 1996-04-01 含有皂苷和固醇的疫苗

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN96193443A Expired - Lifetime CN1111071C (zh) 1995-04-25 1996-04-01 含有皂苷和固醇的疫苗

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNB021529787A Expired - Lifetime CN1289065C (zh) 1995-04-25 1996-04-01 含有皂苷和固醇的疫苗

Country Status (36)

Country Link
EP (3) EP0955059B1 (zh)
JP (1) JP3901731B2 (zh)
KR (1) KR100463372B1 (zh)
CN (3) CN1111071C (zh)
AP (1) AP771A (zh)
AR (1) AR001686A1 (zh)
AT (2) ATE186842T1 (zh)
AU (2) AU693022B2 (zh)
BG (1) BG63491B1 (zh)
BR (1) BR9608199B1 (zh)
CA (1) CA2217178C (zh)
CY (1) CY2588B2 (zh)
CZ (1) CZ296216B6 (zh)
DE (2) DE69637254T2 (zh)
DK (2) DK0955059T3 (zh)
DZ (1) DZ2026A1 (zh)
EA (1) EA000839B1 (zh)
ES (2) ES2140076T5 (zh)
GR (1) GR3031912T3 (zh)
HU (1) HU227944B1 (zh)
IL (1) IL118004A (zh)
MA (1) MA23850A1 (zh)
MY (1) MY134811A (zh)
NO (1) NO322190B1 (zh)
NZ (1) NZ305365A (zh)
OA (1) OA10629A (zh)
PL (1) PL184061B1 (zh)
PT (1) PT955059E (zh)
RO (1) RO119068B1 (zh)
SA (1) SA96170297B1 (zh)
SI (2) SI0822831T2 (zh)
SK (1) SK282017B6 (zh)
TR (1) TR199701252T1 (zh)
TW (1) TW515715B (zh)
UA (1) UA56132C2 (zh)
WO (1) WO1996033739A1 (zh)

Families Citing this family (503)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
GB9620795D0 (en) * 1996-10-05 1996-11-20 Smithkline Beecham Plc Vaccines
RU2127605C1 (ru) * 1996-05-22 1999-03-20 Юрий Леонидович Криворутченко Способ стимулирования гуморального и клеточного иммунного ответа на целевой антиген
AUPO517897A0 (en) 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
AUPO732997A0 (en) * 1997-06-12 1997-07-03 Csl Limited Ganglioside immunostimulating complexes and uses thereof
ATE435661T1 (de) * 1997-08-29 2009-07-15 Antigenics Inc Adjuvant qs-21 enthaltende zusammensetzungen mit polysorbate oder cyclodextrin als hilfsmittel
GB9718901D0 (en) * 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
WO1999011241A1 (en) * 1997-09-05 1999-03-11 Smithkline Beecham Biologicals S.A. Oil in water emulsions containing saponins
GB9724531D0 (en) 1997-11-19 1998-01-21 Smithkline Biolog Novel compounds
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
SI1659179T1 (sl) 1998-02-05 2011-10-28 Glaxosmithkline Biolog Sa S tumorjem povezani antigenski derivati iz MAGE druĹľine in zaporedja nukleinskih kislin, ki jih kodirajo, uporabni za pripravo fuzijskih proteinov in sestavkov za cepljenje
US20020147143A1 (en) 1998-03-18 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
TR200002938T2 (tr) 1998-04-07 2001-02-21 Corixa Corporation Mikrobakteri tüberküloz antijenlerinin füzyon proteinleri ve bunların kullanımı
GB9808866D0 (en) 1998-04-24 1998-06-24 Smithkline Beecham Biolog Novel compounds
GB9817052D0 (en) * 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
EP1102790B1 (en) 1998-08-07 2014-05-07 University of Washington Immunological Herpes Simplex Virus antigens and methods for use thereof
US6692752B1 (en) 1999-09-08 2004-02-17 Smithkline Beecham Biologicals S.A. Methods of treating human females susceptible to HSV infection
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
PT1126876E (pt) 1998-10-16 2007-04-30 Glaxosmithkline Biolog Sa Sistemas adjuvantes e vacinas
WO2000034482A2 (en) 1998-12-08 2000-06-15 Smithkline Beecham Biologicals S.A. Novel compounds derived from neisseria meningitidis
ES2346832T3 (es) 1998-12-08 2010-10-20 Corixa Corporation Compuestos y metodos para el tratamiento y el diagnostico de una infeccion clamidial.
US20020119158A1 (en) 1998-12-17 2002-08-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6579973B1 (en) 1998-12-28 2003-06-17 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
NZ513935A (en) * 1999-02-17 2004-02-27 Csl Ltd Immunogenic complexes and methods relating thereto
JP4812942B2 (ja) * 1999-02-26 2011-11-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル ＣＧモチーフを含むオリゴヌクレオチドを用いるＮｅｉｓｓｅｒｉａ抗原殺菌活性の増強
CA2365102A1 (en) 1999-03-12 2000-09-21 Smithkline Beecham Biologicals S.A. Neisseria meningitidis antigenic polypeptides and encoding polynucleotides and uses thereof
CN1191852C (zh) * 1999-03-19 2005-03-09 史密丝克莱恩比彻姆生物有限公司 疫苗
GB9909077D0 (en) * 1999-04-20 1999-06-16 Smithkline Beecham Biolog Novel compositions
IL145731A0 (en) 1999-04-02 2002-07-25 Corixa Corp A polypetide containing an immunogenic portion of a breast tumor protein and pharmaceutical compositions containing the same
US6558670B1 (en) 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
GB9908885D0 (en) * 1999-04-19 1999-06-16 Smithkline Beecham Biolog Vccine
DE60014076T2 (de) * 1999-04-19 2005-10-13 Glaxosmithkline Biologicals S.A. Adjuvans-zusammensetzung, enthaltend saponin und ein immunstimulatorisches oligonukleotid
US7166573B1 (en) 1999-05-28 2007-01-23 Ludwig Institute For Cancer Research Breast, gastric and prostate cancer associated antigens and uses therefor
US6432411B1 (en) * 1999-07-13 2002-08-13 Hawaii Biotechnology Group Recombinant envelope vaccine against flavivirus infection
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
GB9923176D0 (en) 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
AU1013701A (en) 1999-10-22 2001-05-08 Aventis Pasteur Limited Modified gp100 and uses thereof
WO2001041802A1 (en) * 1999-12-08 2001-06-14 Statens Veterinärmedicinska Anstalt Vaccine adjuvants comprising ginseng plant extract and added aluminium salt
US6905712B2 (en) 1999-12-08 2005-06-14 Statens Veterinarmedicinska Anstalt Vaccine adjuvants comprising ginseng plant extract and added aluminum salt
PT1650221E (pt) 2000-02-23 2012-09-05 Glaxosmithkline Biolog Sa Novos compostos
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
DE60134499D1 (de) * 2000-04-13 2008-07-31 Corixa Corp Immunostimulierende zusammnensetzungen die aminoalkyl glucosaminidephosphat und qs-21 enthalten
WO2001081379A2 (en) 2000-04-21 2001-11-01 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
AU2001258102B2 (en) 2000-05-10 2007-03-01 Aventis Pasteur Limited Immunogenic polypeptides encoded by mage minigenes and uses thereof
ATE526994T1 (de) 2000-06-20 2011-10-15 Corixa Corp Mtb32a antigen aus mycobakterium tuberculosis mit inaktivierter protease aktivität und fusionsproteine die das antigen enthalten
EP1961819A3 (en) 2000-06-28 2008-11-12 Corixa Corporation Composition and methods for the therapy and diagnosis of lung cancer
US20030180316A1 (en) 2000-06-29 2003-09-25 Dominique Boutriau Multivalent vaccine composition
GB0108364D0 (en) 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
UA79735C2 (uk) 2000-08-10 2007-07-25 Глаксосмітклайн Байолоджікалз С.А. Очищення антигенів вірусу гепатиту b (hbv) для використання у вакцинах
US7022830B2 (en) 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
US6680059B2 (en) 2000-08-29 2004-01-20 Tripep Ab Vaccines containing ribavirin and methods of use thereof
US6858590B2 (en) 2000-08-17 2005-02-22 Tripep Ab Vaccines containing ribavirin and methods of use thereof
GB0022742D0 (en) 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
KR100860893B1 (ko) * 2000-10-18 2008-09-29 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신
KR100831139B1 (ko) * 2000-10-18 2008-05-20 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신
EP1201250A1 (en) * 2000-10-25 2002-05-02 SMITHKLINE BEECHAM BIOLOGICALS s.a. Immunogenic compositions comprising liver stage malarial antigens
US7306806B2 (en) 2001-01-26 2007-12-11 United States Of America As Represented By The Secretary Of The Army Recombinant P. falciparum merozoite protein-142 vaccine
AU2002248392A1 (en) * 2001-01-26 2002-08-06 Walter Reed Army Institute Of Research Recombinant plasmodium falciparum merozoite protein-1/42 vaccine
GB0103171D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
WO2002067983A1 (en) * 2001-02-23 2002-09-06 Glaxosmithkline Biologicals S.A. Novel vaccine
AU2002254901A1 (en) * 2001-02-23 2002-10-03 Smithkline Beecham Biologicals S.A. Influenza vaccine formulations for intradermal delivery
US20030031684A1 (en) 2001-03-30 2003-02-13 Corixa Corporation Methods for the production of 3-O-deactivated-4'-monophosphoryl lipid a (3D-MLA)
US7713942B2 (en) * 2001-04-04 2010-05-11 Nordic Vaccine Technology A/S Cage-like microparticle complexes comprising sterols and saponins for delivery of polynucleotides
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
EP1515982A4 (en) 2001-05-09 2005-10-26 Corixa Corp COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF PROSTATE CANCER
US20100221284A1 (en) 2001-05-30 2010-09-02 Saech-Sisches Serumwerk Dresden Novel vaccine composition
MY134424A (en) 2001-05-30 2007-12-31 Saechsisches Serumwerk Stable influenza virus preparations with low or no amount of thiomersal
WO2003005952A2 (en) 2001-07-10 2003-01-23 Corixa Corporation Compositions and methods for delivery of proteins and adjuvants encapsulated in microspheres
ES2615362T3 (es) 2001-07-27 2017-06-06 Glaxosmithkline Biologicals Sa Adhesinas de meningococos
GB0118367D0 (en) 2001-07-27 2001-09-19 Glaxosmithkline Biolog Sa Novel use
US20030138434A1 (en) * 2001-08-13 2003-07-24 Campbell Robert L. Agents for enhancing the immune response
US7361352B2 (en) 2001-08-15 2008-04-22 Acambis, Inc. Influenza immunogen and vaccine
GB0123580D0 (en) * 2001-10-01 2001-11-21 Glaxosmithkline Biolog Sa Vaccine
ES2405405T3 (es) 2001-12-17 2013-05-31 Corixa Corporation Composiciones y procedimientos para la terapia y el diagnóstico de enfermedad inflamatoria del intestino
US7351413B2 (en) 2002-02-21 2008-04-01 Lorantis, Limited Stabilized HBc chimer particles as immunogens for chronic hepatitis
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
DE10211088A1 (de) 2002-03-13 2003-09-25 Ugur Sahin Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
US6861410B1 (en) 2002-03-21 2005-03-01 Chiron Corporation Immunological adjuvant compositions
KR100994748B1 (ko) 2002-04-19 2010-11-17 더 가버닝 카운실 오브 더 유니버시티 오브 토론토 알쯔하이머병의 치료를 위한 면역학적 방법 및 조성물
DK1523582T3 (da) 2002-07-18 2009-03-02 Univ Washington Hurtig, effektiv rensning af HSV-specifikke T-lymfocytter samt HSV-antigener identificeret derved
US20060057160A1 (en) 2002-08-02 2006-03-16 Ralph Biemans Vaccine composition
PT2351579T (pt) 2002-10-11 2016-12-22 Novartis Vaccines And Diagnostics S R L Vacinas polipeptídicas para proteção ampla contra linhagens meningocócicas hipervirulentas
AU2003285932A1 (en) 2002-10-23 2004-05-13 Glaxosmithkline Biologicals S.A. Methods for vaccinating against malaria
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
CA2511907A1 (en) 2003-01-06 2004-07-22 Wyeth Compositions and methods for diagnosing and treating colon cancers
US20050089533A1 (en) * 2003-01-29 2005-04-28 Joseph Frantz Canine vaccines against Bordetella bronchiseptica
ATE395077T1 (de) 2003-01-29 2008-05-15 Pfizer Prod Inc Hundeimpfstoffe gegen bordetella bronchiseptica
CA2514328C (en) 2003-01-30 2020-01-14 Chiron Srl Injectable vaccines against multiple meningococcal serogroups
WO2004087204A2 (en) 2003-04-04 2004-10-14 Pfizer Products Inc. Microfluidized oil-in-water emulsions and vaccine compositions
US7879338B2 (en) 2003-07-21 2011-02-01 Boyce Thompson Institute For Plant Research Vectors and methods for immunization against norovirus using transgenic plants
EP1648500B1 (en) 2003-07-31 2014-07-09 Novartis Vaccines and Diagnostics, Inc. Immunogenic compositions for streptococcus pyogenes
DE10341812A1 (de) 2003-09-10 2005-04-07 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
DE10344799A1 (de) 2003-09-26 2005-04-14 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
PL1961426T3 (pl) 2003-10-02 2012-03-30 Gsk Vaccines S R L Skojarzone szczepionki przeciwko zapaleniu opon mózgowo-rdzeniowych
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
DE602004028262D1 (de) 2003-10-02 2010-09-02 Glaxosmithkline Biolog Sa B. pertussis antigene und ihre verwendung bei der vakzinierung
DE10347710B4 (de) 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
JP5030594B2 (ja) 2003-12-23 2012-09-19 アルボー ビータ コーポレーション Ｈｐｖの発癌性株に対する抗体およびそれらの使用方法
US8080253B2 (en) 2004-02-05 2011-12-20 The Ohio State University Research Foundation Chimeric VEGF peptides
US7767792B2 (en) 2004-02-20 2010-08-03 Ludwig Institute For Cancer Research Ltd. Antibodies to EGF receptor epitope peptides
JP5600375B2 (ja) 2004-03-09 2014-10-01 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド インフルエンザウイルスワクチン
PT1742659E (pt) * 2004-04-05 2013-06-03 Pah Usa 15 Llc Emulsões de óleo em água microfluidizadas e composições de vacinas
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
WO2005105140A2 (en) 2004-04-30 2005-11-10 Chiron Srl Meningococcal conjugate vaccination
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
DE102004023187A1 (de) 2004-05-11 2005-12-01 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
GB0410866D0 (en) 2004-05-14 2004-06-16 Chiron Srl Haemophilius influenzae
DE102004024617A1 (de) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
EP1766034B1 (en) 2004-05-21 2014-03-19 Novartis Vaccines and Diagnostics, Inc. Alphavirus vectors for influenza virus vaccines
WO2006031264A2 (en) 2004-05-25 2006-03-23 Oregon Health And Science University Siv and hiv vaccination using rhcmv- and hcmv-based vaccine vectors
DE602005025342D1 (de) * 2004-05-28 2011-01-27 Glaxosmithkline Biolog Sa Impfstoffzusammensetzungen mit virosomen und einem saponin-adjuvans
WO2006078318A2 (en) 2004-07-29 2006-07-27 Novartis Vaccines And Diagnostics Inc. Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
GB0417494D0 (en) 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
GB0420634D0 (en) * 2004-09-16 2004-10-20 Glaxosmithkline Biolog Sa Vaccines
BRPI0515516B1 (pt) 2004-09-22 2017-08-08 Glaxosmithkline Biologicals S.A. Immunogenic composition, vaccine, method of manufacturing a vaccine, and, use of immunogenic composition.
EP1797173B1 (en) 2004-10-08 2014-05-14 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Modulation of replicative fitness by using less frequently used synonymous codons
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
ES2534752T3 (es) 2004-12-07 2015-04-27 Toray Industries, Inc. Nuevo péptido antigénico contra el cáncer y utilización del mismo
AR052051A1 (es) 2004-12-15 2007-02-28 Neuralab Ltd Anticuerpos ab humanizados usados en mejorar la cognicion
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
GB0503337D0 (en) 2005-02-17 2005-03-23 Glaxosmithkline Biolog Sa Compositions
WO2006089264A2 (en) 2005-02-18 2006-08-24 Novartis Vaccines And Diagnostics Inc. Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
NZ580974A (en) 2005-02-18 2011-05-27 Novartis Vaccines & Diagnostic Immunogens from uropathogenic escherichia coli
GB0504436D0 (en) 2005-03-03 2005-04-06 Glaxosmithkline Biolog Sa Vaccine
AU2006226459A1 (en) 2005-03-23 2006-09-28 Glaxosmithkline Biologicals S.A. Composition
DE102005013846A1 (de) 2005-03-24 2006-10-05 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
US8541007B2 (en) 2005-03-31 2013-09-24 Glaxosmithkline Biologicals S.A. Vaccines against chlamydial infection
EP2392347A3 (en) 2005-03-31 2012-01-18 GlaxoSmithKline Biologicals S.A. Vaccines against chlamydial infection
EA012576B1 (ru) 2005-04-29 2009-10-30 Глаксосмитклайн Байолоджикалс С.А. Новый способ предупреждения или лечения инфекции, вызываемой m.tuberculosis
WO2006138675A2 (en) 2005-06-15 2006-12-28 The Ohio State University Research Foundation Her-2 peptides
GB0513421D0 (en) * 2005-06-30 2005-08-03 Glaxosmithkline Biolog Sa Vaccines
ATE530569T1 (de) 2005-07-01 2011-11-15 Forsyth Dental In Ry For Children Fa Assays zum nachweis von tuberkulose- antigenen, und impfstoffe
EP1762575A1 (en) 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identification of tumor-associated antigens for diagnosis and therapy
GB0519871D0 (en) 2005-09-30 2005-11-09 Secr Defence Immunogenic agents
CA2626253A1 (en) 2005-10-18 2007-04-26 Novartis Vaccines And Diagnostics, Inc. Mucosal and systemic immunizations with alphavirus replicon particles
ES2525518T3 (es) 2005-11-01 2014-12-26 Novartis Vaccines And Diagnostics Gmbh Vacunas virales derivadas de células con niveles reducidos de ADN celular residual
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
PL1945252T3 (pl) 2005-11-04 2013-11-29 Seqirus Uk Ltd Szczepionki zawierające oczyszczone antygeny powierzchniowe otrzymane z wirusów grypy hodowanych w hodowli komórkowej i skwalen jako adiuwant
EP2360175B1 (en) 2005-11-22 2014-07-16 Novartis Vaccines and Diagnostics, Inc. Norovirus and Sapovirus virus-like particles (VLPs)
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
DE102005059242A1 (de) 2005-12-12 2007-06-14 Johannes Gutenberg-Universität Mainz, Vertreten Durch Den Präsidenten Molekulare Marker für eine Tumordiagnose und -therapie
TWI457133B (zh) * 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
PT1973564T (pt) 2005-12-22 2017-01-24 Glaxosmithkline Biologicals Sa Vacina compreendendo conjugados polissacarídicos capsulares de streptococcus pneumoniae
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
US9259463B2 (en) 2006-01-16 2016-02-16 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Chlamydia vaccine
UA92782C2 (ru) 2006-01-17 2010-12-10 Арне Форсгрен Новый поверхностный белок haemophilus influenzae (белок е; ре)
JP6087041B2 (ja) 2006-01-27 2017-03-08 ノバルティス アーゲー 血球凝集素およびマトリックスタンパク質を含むインフルエンザウイルスワクチン
ES2376492T3 (es) 2006-03-23 2012-03-14 Novartis Ag Compuestos de imidazoquinoxalina como inmunomoduladores.
EP2382987A1 (en) 2006-03-24 2011-11-02 Novartis Vaccines and Diagnostics GmbH Storage of influenza vaccines without refrigeration
KR20120042865A (ko) 2006-03-30 2012-05-03 엠브렉스, 인코포레이티드 가금류의 예방접종 방법 및 조성물
JP2009531387A (ja) 2006-03-30 2009-09-03 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物
WO2007126825A2 (en) 2006-03-31 2007-11-08 Novartis Ag Combined mucosal and parenteral immunization against hiv
US10138279B2 (en) 2006-04-13 2018-11-27 Regents Of The University Of Michigan Compositions and methods for Bacillus anthracis vaccination
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
WO2009017467A1 (en) 2007-07-27 2009-02-05 Elan Pharma International Limited Treatment of amyloidogenic diseases
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
EP2390359A1 (en) 2006-06-02 2011-11-30 GlaxoSmithKline Biologicals S.A. Method for identifying whether a patient will be responder or not to immunotherapy based on the differential expression of the ICOS gene
US20100015168A1 (en) 2006-06-09 2010-01-21 Novartis Ag Immunogenic compositions for streptococcus agalactiae
CA2654709A1 (en) 2006-06-12 2007-12-21 Nathalie Devos Neisseria meningitidis lipooligosaccharide vaccine
NZ573931A (en) 2006-06-29 2012-03-30 Craig J Venter Inst Inc Polypeptides from neisseria meningitidis
ES2525572T3 (es) 2006-07-17 2014-12-26 Glaxosmithkline Biologicals S.A. Vacuna antigripal
EA200900032A1 (ru) 2006-07-18 2011-02-28 Глаксосмитклайн Байолоджикалс С.А. Вакцины против малярии
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
WO2008012538A2 (en) 2006-07-25 2008-01-31 The Secretary Of State For Defence Live vaccine strains of francisella
WO2008020330A2 (en) 2006-08-16 2008-02-21 Novartis Ag Immunogens from uropathogenic escherichia coli
CA2662051A1 (en) 2006-09-07 2008-03-13 Glaxosmithkline Biologicals S.A. Vaccine
CA3016948A1 (en) 2006-09-11 2008-03-20 Seqirus UK Limited Making influenza virus vaccines without using eggs
EP2468300B1 (en) * 2006-09-26 2017-12-20 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
CN101522218B (zh) 2006-10-12 2012-09-26 葛兰素史密丝克莱恩生物有限公司 包含水包油乳液佐剂的疫苗
EP2086582B1 (en) 2006-10-12 2012-11-14 GlaxoSmithKline Biologicals s.a. Vaccine comprising an oil in water emulsion adjuvant
ES2630205T3 (es) * 2006-11-20 2017-08-18 Duecom Uso de partículas que contengan lípidos que comprenden saponínas quillaja para el tratamiento del cáncer
CN101553252A (zh) 2006-12-06 2009-10-07 诺华有限公司 包含来自于四株流感病毒的抗原的疫苗
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
KR101532062B1 (ko) 2007-03-02 2015-06-26 글락소스미스클라인 바이오로지칼즈 에스.에이. 신규한 방법 및 조성물
BRPI0809926B8 (pt) 2007-04-04 2021-05-25 Infectious Disease Res Inst composição que compreende antígenos de mycobacterium tuberculosis, polipeptídeo de fusão isolado, polinucleotídeo isolado que codifica o dito polipeptídeo e uso da dita composição para estimular uma resposta imune protetora
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
US9452209B2 (en) 2007-04-20 2016-09-27 Glaxosmithkline Biologicals Sa Influenza vaccine
US20100322949A1 (en) 2007-04-26 2010-12-23 Ludwig Institute For Cancer Research Ltd. Methods for diagnosing and treating astrocytomas
KR20100017569A (ko) 2007-05-02 2010-02-16 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신
WO2008146164A2 (en) 2007-05-25 2008-12-04 Novartis Ag Streptococcus pneumoniae pilus antigens
GB0711858D0 (en) * 2007-06-19 2007-07-25 Glaxosmithkline Biolog Sa Vaccine
BRPI0813644B8 (pt) 2007-06-26 2021-05-25 Glaxosmithkline Biologicals Sa composição imunogênica, vacina, processo para fabricar a mesma, e, uso da composição imunogênica ou vacina
SG182957A1 (en) 2007-06-27 2012-08-30 Novartis Ag Low-additive influenza vaccines
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
PT2173376E (pt) 2007-08-02 2015-07-30 Biondvax Pharmaceuticals Ltd Vacinas de influenza multiepitópicas multiméricas
CA2695421A1 (en) 2007-08-03 2009-02-12 President And Fellows Of Harvard College Chlamydia antigens
UY31285A1 (es) 2007-08-13 2009-03-31 Vacunas
EP2185195A2 (en) 2007-08-16 2010-05-19 Tripep Ab Immunogen platform
ES2561483T3 (es) 2007-09-12 2016-02-26 Glaxosmithkline Biologicals Sa Antígenos mutantes de GAS57 y anticuerpos de GAS57
KR20100085917A (ko) 2007-09-17 2010-07-29 온코메틸롬 사이언시즈 에스에이 개선된 ｍａｇｅ-ａ 발현 검출법
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
EP2060583A1 (en) 2007-10-23 2009-05-20 Ganymed Pharmaceuticals AG Identification of tumor-associated markers for diagnosis and therapy
KR101692819B1 (ko) 2007-10-25 2017-01-05 도레이 카부시키가이샤 면역 유도제
EP2062594A1 (en) 2007-11-21 2009-05-27 Wyeth Farma, S.A. Bluetongue virus vaccine and immunogenic compositions, methods of use and methods of producing same
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
EP2722056A1 (en) 2007-12-03 2014-04-23 President and Fellows of Harvard College CT062, a Chlamydia antigen
EP3118213A1 (en) 2007-12-19 2017-01-18 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Soluble forms of hendra and nipah virus f glycoprotein and uses thereof
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
PT2235046E (pt) 2007-12-21 2012-10-26 Novartis Ag Formas mutantes de estreptolisina o
EP4206231A1 (en) 2007-12-24 2023-07-05 ID Biomedical Corporation of Quebec Recombinant rsv antigens
RU2475496C2 (ru) 2008-02-21 2013-02-20 Новартис Аг МЕНИНГОКОККОВЫЕ ПОЛИПЕПТИДЫ fHBP
CN101998990B (zh) 2008-03-18 2013-11-27 诺华股份有限公司 流感病毒疫苗抗原制备方法的改进
BRPI0910963A2 (pt) 2008-04-16 2016-01-05 Glaxosmithkline Biolog Sa composição imunogênica, método para tratar ou prevenir doença pneumocócica, e , uso de uma composição imunogênica
CN102065880B (zh) 2008-04-18 2015-11-25 综合医院公司 使用自我装配疫苗的免疫治疗
WO2009131673A1 (en) 2008-04-25 2009-10-29 Ludwig Institute For Cancer Research Ltd. Targeted treatment for subjects with estrogen receptor negative and progesterone receptor negative breast cancers
EP2293813A4 (en) 2008-05-23 2012-07-11 Univ Michigan NANO EMULSION VACCINES
AU2009276304B2 (en) 2008-08-01 2012-10-11 Gamma Vaccines Pty Limited Influenza vaccines
DK2324842T3 (da) 2008-08-05 2015-06-22 Toray Industries Immunitetsinducerende middel
GB0815872D0 (en) 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
CN102223876A (zh) 2008-09-26 2011-10-19 纳米生物公司 纳米乳剂治疗性组合物及其使用方法
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
US9974844B2 (en) 2008-11-17 2018-05-22 The Regents Of The University Of Michigan Cancer vaccine compositions and methods of using the same
US20110236470A1 (en) 2008-12-03 2011-09-29 Yaffa Mizrachi Nebenzahl GLUTAMYL tRNA SYNTHETASE (GtS) FRAGMENTS
WO2010079464A1 (en) 2009-01-12 2010-07-15 Novartis Ag Cna_b domain antigens in vaccines against gram positive bacteria
GB0900455D0 (en) 2009-01-13 2009-02-11 Secr Defence Vaccine
GB0901411D0 (en) 2009-01-29 2009-03-11 Secr Defence Treatment
GB0901423D0 (en) 2009-01-29 2009-03-11 Secr Defence Treatment
US20100234283A1 (en) 2009-02-04 2010-09-16 The Ohio State University Research Foundation Immunogenic epitopes, peptidomimetics, and anti-peptide antibodies, and methods of their use
PL2396032T3 (pl) 2009-02-10 2017-05-31 Seqirus UK Limited Szczepionki przeciw grypie o obniżonych zawartościach skwalenu
PE20110992A1 (es) * 2009-02-17 2012-02-12 Glaxosmithkline Biolog Sa Composicion inmunogenica que comprende un antigeno del virus del dengue
EP2221063A1 (en) 2009-02-20 2010-08-25 Ganymed Pharmaceuticals AG Methods and compositions for diagnosis and treatment of cancer
KR102340685B1 (ko) 2009-02-20 2021-12-17 가니메드 파마슈티칼스 게엠베하 암의 진단 및 치료를 위한 방법 및 조성물
EP2221375A1 (en) 2009-02-20 2010-08-25 Ganymed Pharmaceuticals AG Methods and compositions for diagnosis and treatment of cancer
ES2733084T3 (es) 2009-03-06 2019-11-27 Glaxosmithkline Biologicals Sa Antígenos de Chlamydia
US20120039993A1 (en) 2009-03-17 2012-02-16 Glaxosmithkline Biologicals Sa Detection of Gene Expression
KR20120034612A (ko) 2009-04-14 2012-04-12 노파르티스 아게 황색 포도상구균에 대한 면역화를 위한 조성물
GB0906234D0 (en) 2009-04-14 2009-05-20 Secr Defence Vaccine
EP2249159A1 (en) 2009-04-29 2010-11-10 Ganymed Pharmaceuticals AG Identification of tumor-associated markers for diagnosis and therapy
WO2010132833A1 (en) 2009-05-14 2010-11-18 The Regents Of The University Of Michigan Streptococcus vaccine compositions and methods of using the same
PL2437753T3 (pl) 2009-06-05 2017-03-31 Infectious Disease Research Institute Syntetyczne adiuwanty glukopiranozylolipidowe oraz zawierające je kompozycje szczepionek
GB0910046D0 (en) * 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
GB0910045D0 (en) * 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
EP2944320A1 (en) 2009-06-15 2015-11-18 National University of Singapore Influenza vaccine, composition, and methods of use
EP3020412B1 (en) 2009-06-16 2017-10-11 The Regents of the University of Michigan An immunogenic composition comprising nanoemulsion inactivated rsv
PT2445526T (pt) 2009-06-24 2016-08-16 Glaxosmithkline Biologicals Sa Antigénios de rsv recombinantes
US8889146B2 (en) 2009-06-24 2014-11-18 Glaxosmithkline Biologicals, Sa Vaccine
CA2767536A1 (en) 2009-07-07 2011-01-13 Novartis Ag Conserved escherichia coli immunogens
EP4218800A1 (en) 2009-07-15 2023-08-02 GlaxoSmithKline Biologicals S.A. Rsv f protein compositions and methods for making same
MX2012000734A (es) 2009-07-16 2012-01-27 Novartis Ag Inmunogenos destoxificados de escherichia coli.
KR101425405B1 (ko) 2009-07-17 2014-08-01 한림대학교 산학협력단 리포좀에 포집된 올리고뉴클레오타이드 및 에피토프를 포함하는 면역증강용 조성물
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
EP2281579A1 (en) 2009-08-05 2011-02-09 BioNTech AG Vaccine composition comprising 5'-Cap modified RNA
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
CN102596980A (zh) 2009-08-26 2012-07-18 Rna公司 源自脂磷壁酸的糖脂及含有该糖脂的组合物
EP2470204B1 (en) 2009-08-27 2015-12-16 GlaxoSmithKline Biologicals SA Hybrid polypeptides including meningococcal fhbp sequences
WO2011025542A1 (en) 2009-08-31 2011-03-03 Ludwig Institute For Cancer Research Ltd. Seromic analysis of ovarian cancer
US20110110980A1 (en) 2009-09-02 2011-05-12 Wyeth Llc Heterlogous prime-boost immunization regimen
JP2013504556A (ja) 2009-09-10 2013-02-07 ノバルティス アーゲー 気道疾患に対する組み合わせワクチン
NZ598645A (en) * 2009-09-10 2014-07-25 Merial Ltd New vaccine formulations comprising saponin-containing adjuvants
EP2477652B1 (en) 2009-09-16 2015-04-15 Vaxart, Inc. Immunization strategy to prevent h1n1 infection
GB0917457D0 (en) 2009-10-06 2009-11-18 Glaxosmithkline Biolog Sa Method
GB0917002D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Improved shigella blebs
GB0917003D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Purification of bacterial vesicles
US20130022639A1 (en) 2009-09-30 2013-01-24 Novartis Ag Expression of meningococcal fhbp polypeptides
WO2011138636A1 (en) 2009-09-30 2011-11-10 Novartis Ag Conjugation of staphylococcus aureus type 5 and type 8 capsular polysaccharides
WO2011040978A2 (en) 2009-10-02 2011-04-07 Ludwig Institute For Cancer Research Ltd. Immunodominant mhc dr52b restricted ny-eso-1 epitopes, mhc class ii monomers and multimers, and uses thereof
GB0918392D0 (en) 2009-10-20 2009-12-02 Novartis Ag Diagnostic and therapeutic methods
EP2493499A1 (en) 2009-10-27 2012-09-05 Novartis AG Modified meningococcal fhbp polypeptides
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
EP2322555A1 (en) 2009-11-11 2011-05-18 Ganymed Pharmaceuticals AG Antibodies specific for claudin 6 (CLDN6)
CN106432500B (zh) 2009-11-11 2020-06-02 加尼梅德药物公司 密蛋白6(cldn6)特异性的抗体
WO2011067758A2 (en) 2009-12-02 2011-06-09 Protea Vaccine Technologies Ltd. Immunogenic fragments and multimers from streptococcus pneumoniae proteins
US9173954B2 (en) 2009-12-30 2015-11-03 Glaxosmithkline Biologicals Sa Polysaccharide immunogens conjugated to E. coli carrier proteins
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
GB201003924D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
GB201003920D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Method of treatment
US20130011429A1 (en) 2010-03-10 2013-01-10 Jan Poolman Immunogenic composition
EP2366709A1 (en) 2010-03-16 2011-09-21 BioNTech AG Tumor vaccination involving a humoral immune response against self-proteins
AU2011229518B2 (en) 2010-03-16 2015-09-24 Biontech Protein Therapeutics Gmbh Tumor vaccination involving a humoral immune response against self-proteins
SG184188A1 (en) 2010-03-26 2012-10-30 Glaxosmithkline Biolog Sa Hiv vaccine
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
JP2013529894A (ja) 2010-04-07 2013-07-25 ノバルティス アーゲー パルボウイルスｂ１９のウイルス様粒子を生成するための方法
CA2796314A1 (en) 2010-04-13 2011-10-20 Novartis Ag Benzonapthyridine compositions and uses thereof
CN102933267B (zh) 2010-05-28 2015-05-27 泰特里斯在线公司 交互式混合异步计算机游戏基础结构
DK2575870T3 (en) 2010-06-04 2017-02-13 Wyeth Llc vaccine Formulations
GB201009861D0 (en) 2010-06-11 2010-07-21 Novartis Ag OMV vaccines
US8658603B2 (en) 2010-06-16 2014-02-25 The Regents Of The University Of Michigan Compositions and methods for inducing an immune response
EP2404936A1 (en) 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Cancer therapy using CLDN6 target-directed antibodies in vivo
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
WO2012006293A1 (en) 2010-07-06 2012-01-12 Novartis Ag Norovirus derived immunogenic compositions and methods
GB201015132D0 (en) 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
HRP20171164T1 (hr) 2010-09-20 2017-10-20 Biontech Cell & Gene Therapies Gmbh Antigen-specifični t stanični receptori i t stanični epitopi
US9168292B2 (en) 2010-09-27 2015-10-27 Crucell Holland B.V. Heterologous prime boost vaccination regimen against malaria
GB201017519D0 (en) 2010-10-15 2010-12-01 Novartis Vaccines Inst For Global Health S R L Vaccines
AR083454A1 (es) 2010-10-15 2013-02-27 Glaxosmithkline Biolog Sa Antigeno de citomegalovirus
GB201101331D0 (en) 2011-01-26 2011-03-09 Glaxosmithkline Biolog Sa Compositions and uses
US20130345079A1 (en) 2010-10-27 2013-12-26 Infectious Disease Research Institute Mycobacterium tuberculosis antigens and combinations thereof having high seroreactivity
BR112013011420A2 (pt) 2010-11-08 2016-08-02 Infectious Disease Res Inst vacinas compreendendo poliptídeos de nucleosídeo hidrolase não específica e esterol 24-c-metil-transferase (smt) para o tratamento e o diagnóstico de leishmaníase
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
CN106822883A (zh) 2010-12-14 2017-06-13 葛兰素史密丝克莱恩生物有限公司 分枝杆菌抗原组合物
GB201022007D0 (en) 2010-12-24 2011-02-02 Imp Innovations Ltd DNA-sensor
WO2012085668A2 (en) 2010-12-24 2012-06-28 Novartis Ag Compounds
HUE043879T2 (hu) 2011-01-26 2019-09-30 Glaxosmithkline Biologicals Sa RSV-immunizálási rend
WO2012100302A1 (en) 2011-01-27 2012-08-02 Gamma Vaccines Pty Limited Combination vaccines
WO2012114323A1 (en) 2011-02-22 2012-08-30 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
WO2012135177A2 (en) 2011-03-29 2012-10-04 Uab Research Foundation Methods and compositions for cytomegalovirus il-10 protein
GB201106357D0 (en) 2011-04-14 2011-06-01 Pessi Antonello Composition and uses thereof
AU2012243039B2 (en) 2011-04-08 2017-07-13 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
TW201302779A (zh) 2011-04-13 2013-01-16 Glaxosmithkline Biolog Sa 融合蛋白質及組合疫苗
LT2707385T (lt) 2011-05-13 2017-12-11 Glaxosmithkline Biologicals Sa Iš anksto sulieti rsv f antigenai
EP2707390B1 (en) 2011-05-13 2015-12-30 Ganymed Pharmaceuticals AG Antibodies for treatment of cancer expressing claudin 6
JP2014515035A (ja) 2011-05-17 2014-06-26 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ストレプトコッカス・ニューモニエに対するワクチン
AU2012256756B2 (en) 2011-05-19 2017-06-08 Toray Industries, Inc. Immunity induction agent
DK2711017T3 (en) 2011-05-19 2016-11-07 Toray Industries Immunity-inducing agent
WO2012159643A1 (en) 2011-05-24 2012-11-29 Biontech Ag Individualized vaccines for cancer
SMT201900521T1 (it) 2011-05-24 2019-11-13 Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh Vaccini individualizzati per il cancro
PL3892295T3 (pl) 2011-05-24 2023-07-24 BioNTech SE Zindywidualizowane szczepionki przeciwnowotworowe
WO2012170356A1 (en) 2011-06-04 2012-12-13 Rochester General Hospital Research Institute Compositions and methods related to p6 of haemophilus influenzae
AU2012273153A1 (en) 2011-06-21 2013-05-02 Oncofactor Corporation Compositions and methods for the therapy and diagnosis of cancer
EP3332802A1 (en) 2011-07-06 2018-06-13 GlaxoSmithKline Biologicals SA Immunogenic combination compositions and uses thereof
US11058762B2 (en) 2011-07-06 2021-07-13 Glaxosmithkline Biologicals Sa Immunogenic compositions and uses thereof
WO2013009564A1 (en) 2011-07-08 2013-01-17 Novartis Ag Tyrosine ligation process
WO2013016460A1 (en) 2011-07-25 2013-01-31 Novartis Ag Compositions and methods for assessing functional immunogenicity of parvovirus vaccines
GB201113570D0 (en) 2011-08-05 2011-09-21 Glaxosmithkline Biolog Sa Vaccine
GB201114919D0 (en) 2011-08-30 2011-10-12 Glaxosmithkline Biolog Sa Method
WO2013038375A2 (en) 2011-09-14 2013-03-21 Novartis Ag Methods for making saccharide-protein glycoconjugates
PL2758432T3 (pl) 2011-09-16 2019-08-30 Ucb Biopharma Sprl Przeciwciała neutralizujące przeciw głównym egzotoksynom tcda i tcdb z clostridium difficile
WO2013068949A1 (en) 2011-11-07 2013-05-16 Novartis Ag Carrier molecule comprising a spr0096 and a spr2021 antigen
US20130122038A1 (en) 2011-11-14 2013-05-16 The United States Of America As Represented By The Secretary Of The Department Heterologous prime-boost immunization using measles virus-based vaccines
ES2812564T3 (es) 2011-11-23 2021-03-17 Bioven 3 Ltd Proteínas recombinantes y sus usos terapéuticos
EP2785683B1 (en) 2011-11-30 2020-02-05 Ludwig Institute for Cancer Research Ltd. Inkt cell modulators and methods of using the same
WO2013082476A1 (en) 2011-11-30 2013-06-06 Emory University Antiviral jak inhibitors useful in treating or preventing retroviral and other viral infections
GB201120860D0 (en) 2011-12-05 2012-01-18 Cambridge Entpr Ltd Cancer immunotherapy
WO2013108272A2 (en) 2012-01-20 2013-07-25 International Centre For Genetic Engineering And Biotechnology Blood stage malaria vaccine
LT2811981T (lt) 2012-02-07 2019-06-10 Infectious Disease Research Institute Pagerintos adjuvanto kompozicijos, apimančios tlr4 agonistus, ir jų panaudojimo būdai
US20130236484A1 (en) 2012-03-08 2013-09-12 Detectogen Inc. Leishmaniasis antigen detection assays and vaccines
WO2013150518A1 (en) 2012-04-01 2013-10-10 Rappaport Family Institute For Research In The Medical Sciences Extracellular matrix metalloproteinase inducer (emmprin) peptides and binding antibodies
WO2013167153A1 (en) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
CA2873629A1 (en) 2012-05-16 2013-11-21 Immune Design Corp. Vaccines for hsv-2
AU2013265336A1 (en) 2012-05-22 2014-12-04 Novartis Ag Meningococcus serogroup X conjugate
EP2666785A1 (en) 2012-05-23 2013-11-27 Affiris AG Complement component C5a-based vaccine
WO2014005958A1 (en) 2012-07-06 2014-01-09 Novartis Ag Immunogenic compositions and uses thereof
GB201213364D0 (en) 2012-07-27 2012-09-12 Glaxosmithkline Biolog Sa Purification process
BR112015002483A2 (pt) 2012-08-03 2017-11-07 Infectious Disease Res Inst composições e métodos para o tratamento de uma infecção ativa por mycobacterium tuberculosis
AU2013301312A1 (en) 2012-08-06 2015-03-19 Glaxosmithkline Biologicals S.A. Method for eliciting in infants an immune response against RSV and B. pertussis
US20140037680A1 (en) 2012-08-06 2014-02-06 Glaxosmithkline Biologicals, S.A. Novel method
EP2703483A1 (en) 2012-08-29 2014-03-05 Affiris AG PCSK9 peptide vaccine
WO2014043189A1 (en) 2012-09-14 2014-03-20 The Regents Of The University Of Colorado, A Body Corporate Conditionally replication deficient herpes viruses and use thereof in vaccines
AU2013320313B2 (en) 2012-09-18 2018-07-12 Glaxosmithkline Biologicals Sa Outer membrane vesicles
CN105307684A (zh) 2012-10-02 2016-02-03 葛兰素史密丝克莱恩生物有限公司 非直链糖缀合物
AR092896A1 (es) 2012-10-03 2015-05-06 Novartis Ag Composiciones inmunogenicas
KR101819803B1 (ko) 2012-10-24 2018-01-17 플레이틀렛 타게티드 테라퓨틱스, 엘엘씨 혈소판 표적화 치료
WO2014074785A1 (en) 2012-11-08 2014-05-15 Ludwig Institute For Cancer Research Ltd. Methods of predicting outcome and treating breast cancer
US10155031B2 (en) 2012-11-28 2018-12-18 Biontech Rna Pharmaceuticals Gmbh Individualized vaccines for cancer
EP2925355B1 (en) 2012-11-30 2017-11-15 GlaxoSmithKline Biologicals S.A. Pseudomonas antigens and antigen combinations
PL3513806T3 (pl) 2012-12-05 2023-05-15 Glaxosmithkline Biologicals Sa Imunogenna kompozycja
UY34506A (es) 2012-12-10 2014-06-30 Fernando Amaury Ferreira Chiesa Adyuvante de vacunación, preparación y vacunas que lo contienen
KR20250023601A (ko) 2013-03-13 2025-02-18 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 선융합(prefusion) RSV F 단백질 및 이의 용도
CN111978409B (zh) 2013-03-15 2024-01-26 因斯瑞拜奥有限公司 自组装合成蛋白
BE1022174B1 (fr) 2013-03-15 2016-02-24 Glaxosmithkline Biologicals S.A. Vaccin
US9909114B2 (en) 2013-03-28 2018-03-06 Infectious Disease Research Institute Vaccines comprising leishmania polypeptides for the treatment and diagnosis of leishmaniasis
CN105209047B (zh) 2013-04-18 2020-08-18 免疫设计股份有限公司 用于癌症治疗的gla单一疗法
WO2014180490A1 (en) 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
GB201310008D0 (en) 2013-06-05 2013-07-17 Glaxosmithkline Biolog Sa Immunogenic composition for use in therapy
KR20160027019A (ko) 2013-06-26 2016-03-09 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 뎅기 바이러스 백신에 대한 방법 및 조성물
EP3777882A1 (en) 2013-07-30 2021-02-17 BioNTech SE Tumor antigens for determining cancer therapy
WO2015014376A1 (en) 2013-07-31 2015-02-05 Biontech Ag Diagnosis and therapy of cancer involving cancer stem cells
BE1022008B1 (fr) 2013-08-05 2016-02-03 Glaxosmithkline Biologicals S.A. Compositions immunogenes combinees
CA2928700C (en) 2013-11-01 2019-01-15 University Of Oslo Albumin variants and uses thereof
EP2870974A1 (en) 2013-11-08 2015-05-13 Novartis AG Salmonella conjugate vaccines
US9993541B2 (en) 2013-11-13 2018-06-12 University Of Oslo Outer membrane vesicles and uses thereof
US11452767B2 (en) 2013-11-15 2022-09-27 Oslo Universitetssykehus Hf CTL peptide epitopes and antigen-specific t cells, methods for their discovery, and uses thereof
WO2015077442A2 (en) 2013-11-20 2015-05-28 La Jolla Institute For Allergy And Immunology Grass pollen immunogens and methods and uses for immune response modulation
WO2015077434A2 (en) 2013-11-20 2015-05-28 La Jolla Institute For Allergy And Immunology Pan pollen immunogens and methods and uses for immune response modulation
WO2015092710A1 (en) 2013-12-19 2015-06-25 Glaxosmithkline Biologicals, S.A. Contralateral co-administration of vaccines
CA2935620A1 (en) 2013-12-31 2015-07-09 Infectious Disease Research Institute Single vial vaccine formulations
AU2015218769B2 (en) 2014-02-20 2020-09-17 Vaxart, Inc. Formulations for small intestinal delivery
TW201620927A (zh) 2014-02-24 2016-06-16 葛蘭素史密斯克藍生物品公司 Ｕｓｐａ２蛋白質構築體及其用途
WO2015131053A1 (en) 2014-02-28 2015-09-03 Alk-Abelló A/S Polypeptides derived from phl p and methods and uses thereof for immune response modulation
EP3122380B1 (en) * 2014-03-25 2025-03-19 The Government of the United States of America as represented by the Secretary of the Army Non-toxic adjuvant formulation comprising a monophosphoryl lipid a (mpla)-containing liposome composition and a saponin
ES2769647T3 (es) 2014-03-26 2020-06-26 Glaxosmithkline Biologicals Sa Antígenos estafilocócicos mutantes
GB201405921D0 (en) * 2014-04-02 2014-05-14 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
US11571472B2 (en) 2014-06-13 2023-02-07 Glaxosmithkline Biologicals Sa Immunogenic combinations
CA2952118A1 (en) 2014-06-25 2015-12-30 Glaxosmithkline Biologicals S.A. Clostridium difficile immunogenic composition
TW201623329A (zh) 2014-06-30 2016-07-01 亞佛瑞司股份有限公司 針對骨調素截斷變異體的疫苗及單株抗體暨其用途
CN106715458A (zh) 2014-07-18 2017-05-24 华盛顿大学 癌症疫苗组合物及其使用方法
AR101256A1 (es) 2014-07-21 2016-12-07 Sanofi Pasteur Composición vacunal que comprende ipv y ciclodextrinas
WO2016057921A1 (en) 2014-10-10 2016-04-14 Baker Jr James R Nanoemulsion compositions for preventing, suppressing or eliminating allergic and inflammatory disease
WO2016062323A1 (en) 2014-10-20 2016-04-28 Biontech Ag Methods and compositions for diagnosis and treatment of cancer
MY179251A (en) 2014-11-02 2020-11-02 Univ North Carolina Chapel Hill Methods and compositions for recombinant dengue viruses for vaccine and diagnostic development
MX387007B (es) 2014-12-10 2025-03-19 Glaxosmithkline Biologicals Sa Una composición inmunogénica para usarse en el tratamiento o prevención de la infección por staphylococcus aureus.
WO2016128060A1 (en) 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
HK1248554A1 (zh) 2015-02-20 2018-10-19 Board Of Regents, The University Of Texas System 作为疫苗和载体的减毒衣原体的方法和组合物
US10813993B2 (en) 2015-03-03 2020-10-27 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Display platform from bacterial spore coat proteins
EP4226937A3 (en) 2015-03-05 2023-09-27 Northwestern University Non-neuroinvasive viruses and uses thereof
US20180071380A1 (en) 2015-03-20 2018-03-15 The Regents Of The University Of Michigan Immunogenic compositions for use in vaccination against bordetella
CN107427569B (zh) 2015-03-26 2022-12-30 Gpn疫苗有限公司 链球菌疫苗
MX375989B (es) 2015-05-26 2025-03-07 Ohio State Innovation Foundation Estrategia de vacuna basada en nanoparticulas contra el virus de la influenza porcina.
CN108024955A (zh) 2015-06-12 2018-05-11 瓦克萨特公司 用于rsv和诺如病毒抗原的小肠递送的制剂
EP3138579A1 (en) 2015-09-05 2017-03-08 Biomay Ag Fusion protein for use in the treatment of a hepatitis b virus infection
JP2018530620A (ja) * 2015-10-19 2018-10-18 カディラ・ヘルスケア・リミテッド 同一の分野の発明を含有する新規アジュバント及びワクチン組成物
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
GB201518668D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Immunogenic Comosition
SG10202012205XA (en) 2015-11-06 2021-01-28 Adjuvance Technologies Inc Triterpene saponin analogues
GB201522132D0 (en) * 2015-12-15 2016-01-27 Glaxosmithkline Biolog Sa Vaccine
WO2017109698A1 (en) 2015-12-22 2017-06-29 Glaxosmithkline Biologicals Sa Immunogenic formulation
GB201603625D0 (en) 2016-03-02 2016-04-13 Glaxosmithkline Biolog Sa Novel influenza antigens
CN109562154A (zh) 2016-03-10 2019-04-02 爱普瑞希斯有限公司 带有修饰hsp70域的抗原结合融合蛋白
UA125378C2 (uk) 2016-03-14 2022-03-02 Універшітетет І Осло МОДИФІКОВАНІ ІМУНОГЛОБУЛІНИ ЗІ ЗМІНЕНИМ ЗВ'ЯЗУВАННЯМ FcRn
WO2017158421A1 (en) 2016-03-14 2017-09-21 University Of Oslo Anti-viral engineered immunoglobulins
JP7035534B2 (ja) 2016-03-28 2022-03-15 東レ株式会社 免疫誘導剤
WO2017167768A1 (en) 2016-03-28 2017-10-05 Glaxosmithkline Biologicals S.A. Novel vaccine composition
WO2017201390A1 (en) 2016-05-19 2017-11-23 The Regents Of The University Of Michigan Novel adjuvant compositions
WO2017205225A2 (en) 2016-05-21 2017-11-30 Infectious Disease Research Institute Compositions and methods for treating secondary tuberculosis and nontuberculous mycobacterium infections
US11780924B2 (en) 2016-06-21 2023-10-10 University Of Oslo HLA binding vaccine moieties and uses thereof
KR20230019223A (ko) 2016-07-20 2023-02-07 비온테크 에스이 향상된 효능을 갖는 치료를 위한 질병-특이적 표적으로서 네오에피토프의 선택
BR112019003462A2 (pt) 2016-08-23 2019-06-25 Glaxosmithkline Biologicals Sa proteína de fusão, polinucleotídeo, vetor viral, composição farmacêutica, uso de uma proteína de fusão, polinucleotídeo, vetor viral ou composição farmacêutica, e, método para tratar ou prevenir infecção de hepatite b viral ou infecção de hepatite c viral
GB201614799D0 (en) 2016-09-01 2016-10-19 Glaxosmithkline Biologicals Sa Compositions
CA3036218A1 (en) 2016-09-16 2018-03-22 Infectious Disease Research Institute Vaccines comprising mycobacterium leprae polypeptides for the prevention, treatment, and diagnosis of leprosy
EP3295956A1 (en) 2016-09-20 2018-03-21 Biomay Ag Polypeptide construct comprising fragments of allergens
WO2018060288A1 (en) 2016-09-29 2018-04-05 Glaxosmithkline Biologicals S.A. Compositions and methods of treatment of persistent hpv infection
GB201616904D0 (en) 2016-10-05 2016-11-16 Glaxosmithkline Biologicals Sa Vaccine
WO2018077385A1 (en) 2016-10-25 2018-05-03 Biontech Rna Pharmaceuticals Gmbh Dose determination for immunotherapeutic agents
WO2018096396A1 (en) 2016-11-22 2018-05-31 University Of Oslo Albumin variants and uses thereof
GB201620968D0 (en) 2016-12-09 2017-01-25 Glaxosmithkline Biologicals Sa Adenovirus polynucleotides and polypeptides
CA3043790A1 (en) 2016-12-16 2018-06-21 Institute For Research In Biomedicine Novel recombinant prefusion rsv f proteins and uses thereof
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
WO2018178265A1 (en) 2017-03-31 2018-10-04 Glaxosmithkline Intellectual Property Development Limited Immunogenic composition, use and method of treatment
EP3600391A1 (en) 2017-03-31 2020-02-05 GlaxoSmithKline Intellectual Property Development Limited Immunogenic composition, use and method of treatment
IL269904B1 (en) 2017-04-19 2025-06-01 Inst Res Biomedicine Plasmodium sporozoite npdp peptides as vaccine and target novel malaria vaccines and antibodies binding
WO2018200645A1 (en) * 2017-04-25 2018-11-01 Adjuvance Technologies, Inc. Triterpene saponin analogues
WO2018198085A1 (en) 2017-04-28 2018-11-01 Glaxosmithkline Biologicals Sa Vaccination
GB201707700D0 (en) 2017-05-12 2017-06-28 Glaxosmithkline Biologicals Sa Dried composition
GB2600653B (en) * 2017-05-30 2022-11-02 Glaxosmithkline Biologicals Sa Novel methods
WO2018224166A1 (en) 2017-06-09 2018-12-13 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
CN107375921B (zh) * 2017-06-12 2019-10-29 商丘美兰生物工程有限公司 一种甘草皂苷脂质体免疫佐剂及其制备方法
EP3638301A1 (en) 2017-06-16 2020-04-22 GlaxoSmithKline Biologicals S.A. Method of treatment
CA3070034A1 (en) 2017-07-18 2019-01-24 In3Bio Ltd. Synthetic proteins and therapeutic uses thereof
WO2019034575A1 (en) 2017-08-14 2019-02-21 Glaxosmithkline Biologicals Sa Methods of boosting immune responses
WO2019035963A1 (en) 2017-08-16 2019-02-21 Ohio State Innovation Foundation NANOPARTICLE COMPOSITIONS FOR VACCINES AGAINST SALMONELLA
EP3678699A1 (en) 2017-09-07 2020-07-15 University Of Oslo Vaccine molecules
JP2020533338A (ja) 2017-09-07 2020-11-19 ユニバーシティ オブ オスロＵｎｉｖｅｒｓｉｔｙ ｏｆ Ｏｓｌｏ ワクチン分子
EP3678695A1 (en) 2017-09-08 2020-07-15 Infectious Disease Research Institute Liposomal formulations comprising saponin and methods of use
WO2019079594A1 (en) 2017-10-18 2019-04-25 The University Of North Carolina At Chapel Hill METHODS AND COMPOSITIONS FOR VACCINES AGAINST NOVOVIRUS AND DIAGNOSIS OF NOVOVIRUS
GB201721069D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B Immunisation regimen and compositions
GB201721068D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B immunisation regimen and compositions
KR102286397B1 (ko) 2018-02-02 2021-08-05 주식회사 에스엘백시젠 신규 백신 면역보조제
US12281138B2 (en) 2018-03-15 2025-04-22 Biontech Rna Pharmaceuticals Gmbh 5′-cap-trinucleotide- or higher oligonucleotide compounds and their use in stabilizing RNA, expressing proteins in therapy
EP3569612A1 (en) 2018-05-18 2019-11-20 Biomay Ag Treatment and prevention of house dust mite allergies
JP2021526831A (ja) 2018-06-12 2021-10-11 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム アデノウイルスポリヌクレオチド及びポリペプチド
EP3581201A1 (en) 2018-06-15 2019-12-18 GlaxoSmithKline Biologicals S.A. Escherichia coli o157:h7 proteins and uses thereof
WO2020030572A1 (en) 2018-08-07 2020-02-13 Glaxosmithkline Biologicals Sa Processes and vaccines
US20210220462A1 (en) 2018-08-23 2021-07-22 Glaxosmithkline Biologicals Sa Immunogenic proteins and compositions
EP3851120A4 (en) 2018-09-11 2022-04-27 Shanghai Public Health Clinical Center Immunogen for broad-spectrum influenza vaccine and application thereof
WO2020055503A1 (en) 2018-09-14 2020-03-19 Massachusetts Institute Of Technology Nanoparticle vaccine adjuvant and methods of use thereof
AU2018449744A1 (en) 2018-11-16 2021-05-27 Versitech Limited Live attenuated influenza B virus compositions methods of making and using thereof
US20220000779A1 (en) 2018-12-06 2022-01-06 Glaxosmithkline Biologicals Sa Immunogenic compositions
US20220184158A1 (en) 2018-12-21 2022-06-16 Glaxosmithkline Biologicals Sa Methods of inducing an immune response
EP3914708A1 (en) 2019-01-24 2021-12-01 Massachusetts Institute Of Technology Nucleic acid nanostructure platform for antigen presentation and vaccine formulations formed therefrom
GB201901608D0 (en) 2019-02-06 2019-03-27 Vib Vzw Vaccine adjuvant conjugates
US20220339281A1 (en) 2019-03-05 2022-10-27 GalxoSmithKline Biologicals SA Hepatitis b immunisation regimen and compositions
US12318436B2 (en) 2019-05-25 2025-06-03 Access To Advanced Health Institute Composition and method for spray drying an adjuvant vaccine emulsion
KR20220058527A (ko) 2019-06-25 2022-05-09 인3바이오 리미티드 안정화된 키메라 합성 단백질 및 그 치료 용도
WO2021013798A1 (en) 2019-07-21 2021-01-28 Glaxosmithkline Biologicals Sa Therapeutic viral vaccine
US12419949B2 (en) 2019-07-24 2025-09-23 Glaxosmithkline Biologicals Sa Modified human cytomegalovirus proteins
CN114667158A (zh) 2019-08-05 2022-06-24 葛兰素史克生物有限公司 免疫原性组合物
AU2020325279A1 (en) 2019-08-06 2022-03-17 The University Of North Carolina At Chapel Hill Methods and compositions for stabilized recombinant flavivirus E protein dimers
EP3777884A1 (en) 2019-08-15 2021-02-17 GlaxoSmithKline Biologicals S.A. Immunogenic composition
EP3799884A1 (en) 2019-10-01 2021-04-07 GlaxoSmithKline Biologicals S.A. Immunogenic compositions
MX2022004061A (es) 2019-10-02 2022-07-19 Janssen Vaccines & Prevention Bv Peptidos de estafilococo y metodos de uso.
US20220396797A1 (en) 2019-11-15 2022-12-15 Infectious Disease Research Institute Rig-i agonist and adjuvant formulation for tumor treatment
WO2021122551A1 (en) 2019-12-19 2021-06-24 Glaxosmithkline Biologicals Sa S. aureus antigens and compositions thereof
DK4090363T3 (da) 2020-01-16 2024-09-30 Janssen Pharmaceuticals Inc FimH-mutant, sammensætninger dermed og anvendelse deraf
EP4114848A4 (en) 2020-02-26 2024-04-03 Versitech Limited PD-1-BASED VACCINES AGAINST CORONAVIRUS INFECTION
WO2021245611A1 (en) 2020-06-05 2021-12-09 Glaxosmithkline Biologicals Sa Modified betacoronavirus spike proteins
EP4188427A1 (en) 2020-08-03 2023-06-07 GlaxoSmithKline Biologicals S.A. Truncated fusobacterium nucleatum fusobacterium adhesin a (fada) protein and immunogenic compositios thereof
US11225508B1 (en) 2020-09-23 2022-01-18 The University Of North Carolina At Chapel Hill Mouse-adapted SARS-CoV-2 viruses and methods of use thereof
US20230416309A1 (en) 2020-10-23 2023-12-28 Jiangsu Provincial Center For Disease Control And Prevention (Public Health Research Institute Of Ji Fusion protein and application thereof
MX2023005018A (es) 2020-10-28 2023-05-16 Sanofi Pasteur Liposomas que contienen un agonista de tlr4, preparacion y usos de los mismos.
WO2022117595A2 (en) 2020-12-02 2022-06-09 Glaxosmithkline Biologicals Sa Novel antigens
AR124604A1 (es) 2021-01-12 2023-04-12 Janssen Pharmaceuticals Inc Mutantes de fimh, composiciones con los mismos y uso de los mismos
EP4032547A1 (en) 2021-01-20 2022-07-27 GlaxoSmithKline Biologicals S.A. Hsv1 fce derived fragements for the treatment of hsv
US20240148849A1 (en) 2021-02-22 2024-05-09 Glaxosmithkline Biologicals Sa Immunogenic composition, use and methods
US20220288181A1 (en) 2021-03-12 2022-09-15 Northwestern University Antiviral vaccines using spherical nucleic acids
EP4313138A1 (en) 2021-03-30 2024-02-07 Viravaxx AG Sars-cov-2 subunit vaccine
EP4313132A1 (en) 2021-03-31 2024-02-07 Vib Vzw Vaccine compositions for trypanosomatids
BR112023019874A2 (pt) 2021-04-01 2023-11-07 Janssen Pharmaceuticals Inc Produção de bioconjugados de e. coli o18
WO2023274860A1 (en) 2021-06-28 2023-01-05 Glaxosmithkline Biologicals Sa Novel influenza antigens
WO2023046898A1 (en) 2021-09-23 2023-03-30 Viravaxx AG Hbv vaccine inducing pres-specific neutralizing antibodies
WO2023079528A1 (en) 2021-11-05 2023-05-11 King Abdullah University Of Science And Technology Compositions suitable for use in a method for eliciting cross-protective immunity against coronaviruses
WO2023079529A1 (en) 2021-11-05 2023-05-11 King Abdullah University Of Science And Technology Re-focusing protein booster immunization compositions and methods of use thereof
CN118510790A (zh) 2021-12-13 2024-08-16 美国政府(由卫生和人类服务部的部长所代表) 噬菌体λ-疫苗系统
US20230190920A1 (en) 2021-12-19 2023-06-22 Massachusetts Institute Of Technology Compositions and methods for long-lasting germinal center responses to a priming immunization
WO2023144665A1 (en) 2022-01-28 2023-08-03 Glaxosmithkline Biologicals Sa Modified human cytomegalovirus proteins
US20250161429A1 (en) 2022-02-14 2025-05-22 University Of Georgia Research Foundation, Inc. Pan-pneumovirus vaccine compositions and methods of use thereof
IL321069A (en) 2022-12-01 2025-07-01 Pfizer Pneumococcal conjugate vaccine preparations
WO2024130009A1 (en) 2022-12-14 2024-06-20 Yale University Compositions and methods of use thereof for the treatment of virally driven cancers
WO2024133160A1 (en) 2022-12-19 2024-06-27 Glaxosmithkline Biologicals Sa Hepatitis b compositions
GB202219228D0 (en) 2022-12-20 2023-02-01 Glaxosmithkline Biologicals Sa Novel influenza antigens
WO2024160901A1 (en) 2023-02-02 2024-08-08 Glaxosmithkline Biologicals Sa Immunogenic composition
GB202303250D0 (en) 2023-03-06 2023-04-19 King S College London Method and compounds
WO2024228167A1 (en) 2023-05-03 2024-11-07 Iox Therapeutics Inc. Inkt cell modulator liposomal compositions and methods of use
WO2024241172A2 (en) 2023-05-19 2024-11-28 Glaxosmithkline Biologicals Sa Methods for eliciting an immune response to respiratory syncycial virus and streptococcus pneumoniae infection
WO2025163460A2 (en) 2024-01-30 2025-08-07 Pfizer Inc. Vaccines against respiratory diseases
WO2025191415A1 (en) 2024-03-11 2025-09-18 Pfizer Inc. Immunogenic compositions comprising conjugated escherichia coli saccharides and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ230747A (en) * 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
WO1990007935A1 (en) * 1989-01-23 1990-07-26 Auspharm International Ltd. Vaccine composition
GB8919819D0 (en) * 1989-09-01 1989-10-18 Coopers Animal Health Complexes having adjuvant activity
NL9002314A (nl) * 1990-10-23 1992-05-18 Nederlanden Staat Immunogene complexen, in het bijzonder iscoms.
AU661404B2 (en) * 1992-06-25 1995-07-20 Smithkline Beecham Biologicals (Sa) Vaccine composition containing adjuvants
WO1994019013A1 (en) * 1993-02-19 1994-09-01 Smithkline Beecham Corporation Influenza vaccine compositions containing 3-o-deacylated monophosphoryl lipid a
EP0689454B2 (en) * 1993-03-23 2005-02-23 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccine compositions containing 3-o deacylated monophosphoryl lipid a
DK0705109T4 (da) * 1993-05-25 2004-05-10 Wyeth Corp Adjuvanser til vacciner mod respiratorisk syncytialvirus
AUPM873294A0 (en) * 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
GB9718901D0 (en) † 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine

Also Published As

Publication number Publication date
ES2140076T3 (es) 2000-02-16
DK0822831T4 (da) 2006-12-27
HK1025244A1 (zh) 2000-11-10
WO1996033739A1 (en) 1996-10-31
HU227944B1 (en) 2012-06-28
EP0955059B1 (en) 2007-09-19
DE69605296D1 (de) 1999-12-30
CN1515245A (zh) 2004-07-28
ES2140076T5 (es) 2007-04-16
GR3031912T3 (en) 2000-02-29
KR19990008003A (ko) 1999-01-25
EA199700272A1 (ru) 1998-04-30
EP0822831B1 (en) 1999-11-24
DK0955059T3 (da) 2007-12-17
OA10629A (en) 2002-09-16
DE69637254T2 (de) 2008-06-19
NO974859D0 (no) 1997-10-21
EP0955059A2 (en) 1999-11-10
DE69605296T3 (de) 2007-02-15
PL184061B1 (pl) 2002-08-30
ATE373487T1 (de) 2007-10-15
SI0822831T1 (en) 2000-02-29
CA2217178A1 (en) 1996-10-31
HUP9801560A3 (en) 1999-07-28
AU6987398A (en) 1998-07-23
BR9608199A (pt) 1999-05-18
CN1480214A (zh) 2004-03-10
SK282017B6 (sk) 2001-10-08
EP0822831A1 (en) 1998-02-11
RO119068B1 (ro) 2004-03-30
SI0822831T2 (sl) 2006-12-31
NO322190B1 (no) 2006-08-28
CA2217178C (en) 2009-09-29
DZ2026A1 (fr) 2002-07-21
AU5334596A (en) 1996-11-18
ATE186842T1 (de) 1999-12-15
NZ305365A (en) 1999-05-28
NO974859L (no) 1997-10-21
AU693022B2 (en) 1998-06-18
BG101995A (en) 1998-11-30
MA23850A1 (fr) 1996-12-31
PT955059E (pt) 2007-11-27
UA56132C2 (uk) 2003-05-15
AP9701123A0 (en) 1997-10-31
BR9608199B1 (pt) 2009-05-05
SI0955059T1 (sl) 2008-02-29
CZ296216B6 (cs) 2006-02-15
JPH11504020A (ja) 1999-04-06
KR100463372B1 (ko) 2005-02-28
CN1111071C (zh) 2003-06-11
BG63491B1 (bg) 2002-03-29
AR001686A1 (es) 1997-11-26
CN1289065C (zh) 2006-12-13
TR199701252T1 (xx) 1998-03-21
MX9708226A (es) 1998-06-30
AP771A (en) 1999-10-07
EP0955059A3 (en) 2000-07-12
HUP9801560A1 (hu) 1998-10-28
EP0884056A1 (en) 1998-12-16
MY134811A (en) 2007-12-31
EP0822831B2 (en) 2006-08-23
AU699213B2 (en) 1998-11-26
EA000839B1 (ru) 2000-04-24
SK144297A3 (en) 1998-05-06
PL322968A1 (en) 1998-03-02
SA96170297B1 (ar) 2005-11-15
HK1009086A1 (zh) 1999-05-28
DE69637254D1 (de) 2007-10-31
DE69605296T2 (de) 2000-05-18
DK0822831T3 (da) 2000-05-01
IL118004A0 (en) 1996-08-04
TW515715B (en) 2003-01-01
CN1182370A (zh) 1998-05-20
IL118004A (en) 1999-11-30
CZ337997A3 (cs) 1998-03-18
ES2293708T3 (es) 2008-03-16
JP3901731B2 (ja) 2007-04-04
CY2588B2 (en) 2009-11-04

Similar Documents

Publication Publication Date Title
CN1248737C (zh) 含有皂苷和固醇的疫苗
CN1122530C (zh) 疫苗
JP4028593B2 (ja) ３−ｏ脱アシル化モノホスホリルリピドａ含有ワクチン組成物
CN1086589C (zh) 疫苗
US6846489B1 (en) Vaccines containing a saponin and a sterol
HK1060297A (zh) 含有皂苷和固醇的疫苗
HK1023499B (zh) 含有3-0脱酰单磷酰基类酯a的疫苗组合物
HK1022074B (zh) 含有佐剂的疫苗合剂
HK1010097B (zh) 含有辅药的疫苗合剂
HK1009086B (zh) 含有皂角苷和固醇的疫苗
HK1011930C (zh) 含有3-o脱酰单磷酰基脂质a的疫苗组成
HK1011930B (zh) 含有3-o脱酰单磷酰基脂质a的疫苗组成
MXPA97008226A (es) Vacunas que contienen una saponina y un esterol
HK1020263A (zh) 包含皂苷和固醇的疫苗

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1060297

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1060297

Country of ref document: HK

CX01 Expiry of patent term

Granted publication date: 20060405

EXPY Termination of patent right or utility model